Document:

Amended and Restated Investors' Rights Agreement

 Exhibit 4.2 
 TISSUELINK MEDICAL, INC. 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 
 This Amended and Restated Investors’ Rights Agreement is made as of February 12, 2007, by and among TissueLink Medical, Inc., a Delaware
corporation (the “Company”), the investors listed on Schedule A hereto (each a “Purchaser” and collectively the “Purchasers”), Medtronic, Inc. (“Medtronic” and, together with the
Purchasers, the “Investors”), and the other stockholders of the Company listed from time to time on Schedule B hereto (the “Management Stockholders” and, together with the Investors, the
“Stockholders”) and amends and restates in its entirety the Amended and Restated Investors’ Rights Agreement dated as of January 31, 2003 (the “2003 Investors’ Rights Agreement”) entered into in
connection with the issuance of shares of Series D Convertible Preferred Stock of the Company (“Series D Preferred”) to certain of the Investors, as supplemented by the Instrument of Joinder to Amended and Restated Investors’
Rights Agreement of TissueLink Medical, Inc., dated May 24, 2005, whereby Horizon Technology Funding Company II LLC and Horizon Technology Funding Company III LLC were granted certain rights with respect to registration. The 2003
Investors’ Rights Agreement amended and restated in its entirety the Amended and Restated Investors’ Rights Agreement dated as of January 15, 2002 (the “January 2002 Investors’ Rights Agreement”) entered into in
connection with the issuance of shares of Series C Convertible Preferred Stock of the Company (“Series C Preferred”) to certain of the Investors. The January 2002 Investors’ Rights Agreement amended and restated in its entirety
the Amended and Restated Investors’ Rights Agreement dated as of September 11, 2000 (the “2000 Investors’ Rights Agreement”) entered into in connection with the issuance of shares of Series B Convertible Preferred
Stock of the Company (“Series B Preferred”) to certain of the Investors. The 2000 Investors’ Rights Agreement amended and restated in its entirety the Investors’ Rights Agreement dated as of August 9, 1999 (the
“1999 Investors’ Rights Agreement”) entered into in connection with the issuance of shares of Series A Convertible Preferred Stock of the Company (“Series A Preferred”) to certain of the Investors. 

WHEREAS, the Company and certain of the Investors have entered into the Series E Convertible Preferred Stock Purchase Agreement (the “Series E
Stock Purchase Agreement”) as of February 12, 2007 pursuant to which the Company agrees to issue shares of Series E Convertible Preferred Stock of the Company (the “Series E Preferred”) to certain of the Investors; and

 WHEREAS, the amendment of the 2003 Investors’ Rights Agreement to incorporate the terms and conditions set forth herein is a
condition precedent to certain of the Investors’ obligations pursuant to the Series E Stock Purchase Agreement; 
 NOW, THEREFORE, the
parties hereto agree as follows: 
 1. Right of First Offer. Subject to the terms and conditions specified in this
Section 1, the Company hereby grants to each Participating Holder (as defined below) and New Holder (as defined below), a right of first offer with respect to future issuances or sales by the Company of the Company Offered Shares (as
hereinafter defined). 

 For purposes of this Agreement, a “Participating Holder” means an Investor who purchases its full pro rata
share (based on the proportion of the number of shares of common stock, $.01 par value, of the Company ( “Common Stock”) issued and held, or then issuable upon conversion and exercise of all convertible or exercisable securities
then held, by such Investor bears to the total number of shares of Common Stock then outstanding (assuming full conversion and exercise of all convertible or exercisable securities)) of 21, 635, 656 shares of Series E Preferred Stock pursuant to the
Series E Stock Purchase Agreement (collectively referred to as the “Participating Holders”). A list of the Participating Holders as of the date of the Initial Closing (as defined in the Series E Stock Purchase Agreement) is attached as
Schedule C. 
 For purposes of this Agreement, a “New Holder” means any Person (as defined below) who is not a Stockholder as of
February 8, 2007 who subsequently purchases at least 100,000 shares of Series E Preferred (collectively referred to as the “New Holders”). A list of New Holders as of the date of the Initial Closing (as defined in the Series E Stock
Purchase Agreement) is attached as Schedule D. 
 Each time the Company proposes to offer any shares of, or securities convertible into or exercisable
for any shares of, any class of the Company’s capital stock (the “Company Offered Shares”), the Company shall first make an offering of such Company Offered Shares to each Participating Holder and New Holder in accordance with
the following provisions: 
 1.1. Notice of Sales. The Company shall deliver a notice by certified mail (the
“Notice”) to the Participating Holders and New Holders stating (i) its bona fide intention to offer such Company Offered Shares, (ii) the number and class or series of the shares of the Company’s capital stock
constituting the Company Offered Shares and (iii) the price and terms, if any, upon which it proposes to offer such Company Offered Shares. 
 1.2. Exercise of Right. 
 (a) Within 15 calendar days after delivery of the Notice, each Participating Holder and New
Holder may elect to purchase, at the price and on the terms specified in the Notice, up to that portion of the Company Offered Shares which equals the proportion that the number of shares of Series E Preferred issued and held, or then issuable upon
conversion and exercise of all convertible or exercisable securities then held, by such Participating Holder or New Holder bears to the total number of shares of Series E Preferred then outstanding (assuming full conversion and exercise of all
convertible or exercisable securities). The proportion so computed is referred to herein as the “Pro Rata Proportion.” The Company shall promptly, in writing, inform each Participating Holder and New Holder that purchases all the
shares available to it (each, a “Fully-Exercising Investor”) of any other Participating Holder’s or New Holder’s failure to do likewise. During the fifteen (15) day period commencing after receipt of such information,
each Fully-Exercising Investor shall be entitled to purchase an additional number of Company Offered Shares equal to such Fully-Exercising Investor’s Pro Rata Proportion multiplied by the number of Company Offered Shares which Participating
Holders and New Holders were entitled to purchase but did not purchase. 
  

 2 

 (b) The Company may, during the 45-day period following the expiration of the period provided in
Section 1.2(a), offer the remaining portion of the Company Offered Shares not purchased by the Participating Holders and New Holders to any person or persons at a price not less than, and upon terms no more favorable to the offeree than, those
specified in the Notice. If the Company does not enter into an agreement for the sale of the Company Offered Shares within such period, or if such agreement is not consummated within 45 days of its execution, the right provided hereunder shall be
deemed to be revived and such Company Offered Shares shall not be offered unless first reoffered to the Participating Holders and New Holders in accordance herewith. 
 1.3. Exceptions. Notwithstanding the foregoing, the right of first offer in this Section 1 shall not apply: (1) to the issuance of up to 15,462,278 shares of Common Stock, or options
exercisable therefor, (subject to equitable adjustment in the event of any stock split, combination, reclassification or other similar event involving the Common Stock), to officers, directors, employees, consultants and advisors of the Company
under a plan or agreement approved by the Board of Directors of the Company; (2) under any of the circumstances that would constitute an Extraordinary Common Stock Event (as defined in Article 5, Section 9 of the Amended and Restated
Certificate of Incorporation of the Company), occurring other than in connection with a merger or consolidation of the Company with or into another corporation or a sale of all or substantially all of the assets of the Company; (3) to the
issuance of shares of Common Stock upon the conversion of any shares of Preferred Stock; (4) to the issuance of securities in connection with a bona fide business acquisition by the Company approved by the Board of Directors of the Company,
whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise; (5) to the issuance of up to 100,000 shares of Common Stock, or warrants exercisable therefor, (subject to equitable adjustment in the event of any stock
split, combination, reclassification or other similar event involving the Common Stock), to financial institutions or lessors in connection with commercial credit arrangements, equipment financings, or similar transactions approved by the Board of
Directors of the Company; (6) to the issuance of shares of Common Stock or Series D Preferred upon the exercise of certain warrants issued by the Company to Medtronic under the License Agreement dated August 9, 1999, as amended (the
“Medtronic Warrants”) or to the issuance of shares of Common Stock upon the exercise of that certain warrant issued by the Company to Brown Brothers Harriman & Co. dated September 3, 2002 (the “Brown Brothers
Warrant”); (7) to the issuance of shares of Series B Preferred upon the exercise of the Series B Warrants issued pursuant to the Series B Convertible Preferred Stock and Warrant Purchase Agreement dated as of September 1, 2000
(the “Series B Warrants”); (8) to the issuance of any other securities granted, awarded or issued by the Company prior to January 31, 2003 (and securities issued by the Company after that date in exchange for or upon
exercise of such securities); (9) to the issuance of securities pursuant to the Series E Stock Purchase Agreement or to the issuance of securities in exchange for or upon the conversion of such shares of Series E Preferred; (10) to the
issuance of any shares of Common Stock pursuant to the Series E Dividend (as defined in Article 5, Section 7(b) of the Amended and Restated Certificate of Incorporation of the Company); (11) to the issuance of any securities in connection
with a Qualified IPO (as defined below); or (12) with respect to any issuance as to which the holders of a majority of the shares of Preferred Stock outstanding immediately prior to such issuance, voting together as a single class, so elect.

  

 3 

 1.4. Termination. The rights set forth in this Section 1 shall terminate as to each
Participating Holder and New Holder and be of no further force or effect (i) upon the consummation of a Qualified IPO, or (ii) when the Company shall sell, convey, or otherwise dispose of all or substantially all of its property or
business or merge into or consolidate with any other corporation (other than a wholly-owned subsidiary corporation) or effect any other transaction or series of related transactions in which more than 50% of the voting power of the Company is
disposed of, other than a merger effected exclusively for the purpose of changing the domicile of the Company (a “Change of Control”). The term “Qualified IPO” means an underwritten public offering on a firm
commitment basis pursuant to an effective registration statement under the Securities Act of 1933 as amended (the “Securities Act”) covering the offer and sale of Common Stock for the account of the Company at a price greater than
or equal to $2.318 per share of Common Stock (as adjusted for stock splits, stock dividends and the like) in which the aggregate proceeds to the Company exceed $25,000,000. 
 2. Transfer Restrictions; Right of First Refusal. 
 2.1. General Transfer
Restrictions. No Stockholder shall Transfer any Shares or allow the power to vote Shares to be exercised by any other Person (except through ordinary proxies, revocable at the option of such Stockholder) except as provided in this
Section 2, Section 3 and Section 4. Any attempted Transfer of Shares not permitted under the terms of Section 2, Section 3 and Section 4 shall be null and void, and the Company shall not in any way give effect to any
such impermissible Transfer. For purposes of this Agreement: 
 “Affiliate” means, with respect to any specified Person,
(a) any other Person which directly or indirectly controls, is controlled by, or is under common control with, such specified Person (for the purposes of this definition, “control” (including, with correlative meanings, the terms
“controlling,” “controlled by,” and “under common control with”), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management or
policies of such Person, whether through the ownership of voting securities, by agreement or otherwise) and (b) with respect to any natural Person, any Member of the Immediate Family of such natural Person. 
 “Members of the Immediate Family” means, with respect to any individual, each spouse or child or other descendants of such individual,
each trust created solely for the benefit of one or more of the aforementioned Persons and their spouses and each custodian or guardian of any property of one or more of the aforementioned Persons in his or her capacity as such custodian or
guardian. 
 “Person” means an individual, partnership, corporation, company, association, trust, joint venture,
unincorporated organization and any governmental department or agency or political subdivision. 
  

 4 

 “Preferred Stock” means the Series A Preferred, the Series A-1 Convertible Preferred
Stock of the Company (the “Series A-1 Preferred”), the Series B Preferred, the Series B-1 Convertible Preferred Stock of the Company (the “Series B-1 Preferred”), the Series C Preferred, the Series C-1 Preferred Stock of the
Company (the “Series C-1 Preferred”), the Series D Preferred, the Series D-1 Preferred Stock of the Company (the “Series D-1 Preferred”) and the Series E Preferred and the Series E-1 Preferred Stock of the Company (the
“Series E Preferred”). 
 “Shares” means all shares of Common Stock and Preferred Stock originally issued to, or
issued with respect to shares originally issued to, or held by, a Stockholder, whenever issued, including without limitation all shares of Common Stock and Preferred Stock issued pursuant to the exercise of any option or warrant. 
 “Transfer” means any sale, pledge, assignment, encumbrance or other transfer or disposition of any Shares to any other Person, whether
directly, indirectly, voluntarily, involuntarily, by operation of law, pursuant to judicial process or otherwise. 
 2.2. Right of
First Refusal. Subject to the terms and conditions specified in this Section 2, each Stockholder hereby grants to each of the Participating Holders and New Holders a right of first refusal with respect to future Transfers of Shares held
by such Stockholder. Each time any Stockholder (the “Offering Stockholder”) proposes to Transfer any Shares held by such Stockholder (the “Stockholder Offered Shares”), the Offering Stockholder shall first make an
offering of such Stockholder Offered Shares to each of the other Participating Holders and New Holders in accordance with the provisions of Sections 2.3 through 2.4. 
 2.3. Notice of Sales. The Offering Stockholder shall deliver a notice by certified mail (“Stockholder Offer Notice”) to the other Participating Holders and New Holders, with a copy to
the Company, stating (i) the Offering Stockholder’s bona fide intention to Transfer such Stockholder Offered Shares, (ii) the number and class or series of the shares of the Company’s capital stock constituting the Stockholder
Offered Shares and (iii) the price and terms, if any, upon which the Offering Stockholder proposes to Transfer such Stockholder Offered Shares. 
 2.4. Exercise of Right. 
 (a) Within 15 calendar days after delivery of the Stockholder Offer
Notice, each of the Participating Holders and New Holders may elect to purchase, at the price and on the terms specified in the Stockholder Offer Notice, up to its Pro Rata Proportion of the Stockholder Offered Shares. The Offering Stockholder shall
promptly, in writing, inform each Participating Holder or New Holder that purchases all the shares available to it (each, a “Fully-Exercising Stockholder”) of any other Participating Holder’s or New Holder’s failure to do
likewise. During the fifteen (15) day period commencing after receipt of such information, each Fully-Exercising Stockholder shall be entitled to purchase an additional number of Stockholder Offered Shares equal to (1) the proportion that
the number of shares of Series E Preferred issued and held, or then issuable upon conversion and exercise of all convertible or exercisable securities then held, by such Fully-Exercising Stockholder bears to the total number of shares of Series E
Preferred then held by (assuming full conversion and exercise of all convertible or exercisable securities) all Fully-Exercising Stockholders multiplied by (2) the number of Stockholder Offered Shares which Participating Holders and New
Holders were entitled to purchase but did not purchase. 
  

 5 

 (b) The Offering Stockholder may, during the 45-day period following the expiration of the period
provided in Section 2.4(a), Transfer the remaining portion of the Stockholder Offered Shares not purchased by the other Participating Holders and New Holders to any person or persons at a price not less than, and upon terms no more favorable to
the purchaser or transferee than, those specified in the Stockholder Offer Notice. The transferee of such Stockholder Offered Shares shall be required to comply with the provisions of Section 2.7. If the Offering Stockholder does not Transfer,
or enter into an agreement for the Transfer of, the Stockholder Offered Shares within such period, or if such agreement is not consummated within 45 days of its execution, the right provided hereunder shall be deemed to be revived and such
Stockholder Offered Shares shall not be Transferred unless first reoffered to the other Participating Holders and New Holders in accordance with this Section 2. 
 2.5. Exceptions. Notwithstanding the foregoing, the right of first refusal set forth in this Section 2 shall not be applicable to: (i) any Transfer by a Stockholder of Shares to an Affiliate of
such Stockholder; (ii) any Transfer by an Investor to any partner, limited partner, retired partner, holder of limited liability company interest or stockholder of the Investor, (iii) upon the death of any Stockholder who is a natural
person, the distribution of Shares by the will or other instrument taking effect at death of such Stockholder or by applicable laws of descent and distribution to such Stockholder’s estate, executors, administrators and personal
representatives, and then to such Stockholder’s heirs, legatees or distributees, whether or not such recipients are Members of the Immediate Family of such Stockholder; or (iv) any repurchase by the Company of Common Stock owned by an
employee, officer, director, or consultant of the Company at a price that is equal to or less than the original purchase price of such shares in connection with the termination of such person’s employment or relationship with the Company
pursuant to a stock restriction agreement with the Company; provided, that, in all such cases, (x) the Stockholder shall provide the Company and the Investors with notice of such transfer prior to effecting it, and (y) the
transferee shall comply with the requirements of Section 2.7 relating to Permitted Transferees. Notwithstanding the foregoing, the right of first refusal set forth in this Section 2 shall also not be applicable to a Transfer by a
Stockholder in a Public Offering registered under the Securities Act. 
 2.6. Termination. The rights set forth in this
Section 2 shall terminate as to each Stockholder and be of no further force or effect (i) upon the consummation of a Qualified IPO or (ii) upon a Change of Control. 
 2.7. Permitted Transferees. No Transfer permitted under the terms of this Section 2 or under the terms of Section 4 shall be
effective unless the transferee of such Shares (each, a “Permitted Transferee”) has delivered to the Company a written acknowledgment and agreement in form and substance reasonably satisfactory to the Company that such Shares to be
received by such Permitted Transferee shall remain subject to all of the provisions of this Agreement and that such Permitted Transferee shall be bound by, and shall be a party to, this Agreement as a holder of Shares; provided,
however, that no Transfer by any holder of Shares to a Permitted Transferee shall relieve such holder of any of its obligations hereunder. Any Permitted Transferee who receives Shares from a Management Stockholder in a Transfer under this
Agreement shall be deemed to be a Management Stockholder upon such Transfer with respect to such Shares. 
  

 6 

 3. Take-Along Right. 
 3.1. General. Subject to prior compliance with Section 2, if the Majority Stockholders (for purposes of this Section 3, collectively, the “Proposed Sellers”) determine to
Transfer for value in a bona fide arms-length transaction all of the Shares then owned by such Stockholders to any person not affiliated with or otherwise related to any of the Proposed Sellers (for purposes of this Section 3, the
“Proposed Buyer”), then, upon 30 days written notice to the other Stockholders in compliance with the terms of Section 3.2, each of the other Stockholders shall be obligated to Transfer to the Proposed Buyer all of the Shares
then owned by such Stockholder in the manner and on the terms set forth in the Take Along Notice in the same transaction at the closing thereof, provided that all of the holders of a particular class of shares of capital stock of the Company shall
receive the same form and its pro rata amount of consideration upon the closing of such transaction. For purposes of this Section 3, “Majority Stockholders” means the holders of a majority of the shares of Preferred Stock then
outstanding, voting together as a single class, and 66 2/3% or more of the shares of Series E Preferred then outstanding, voting together as a single class. 
 3.2. Take Along Notice. If the Proposed Sellers elect to exercise their rights under this Section 3, a written notice (the “Take Along Notice”) shall be furnished by the Proposed
Sellers to the other Stockholders. The Take Along Notice may consist of the offer received by the Proposed Sellers for the purchase of their Shares. The Take Along Notice shall set forth the principal terms of the proposed sale insofar as it relates
to the Shares, including the maximum and minimum purchase price, and the name and address of the Proposed Buyer. If at the end of the one hundred eightieth (180th) day following the date of receipt by such other Stockholders of the Take Along
Notice the Proposed Sellers have not completed the proposed sale, the other Stockholders shall be released from their obligations under this Section 3 as it relates to the proposed sale, the Take Along Notice shall be null and void, and it
shall be necessary for a separate Take Along Notice to be furnished and the terms and provisions of this Section 3 separately complied with, in order to consummate such sale pursuant to this Section 3. 
 3.3. Termination. The provisions set forth in this Section 3 shall terminate and be of no further force or effect (i) upon the
consummation of a Qualified IPO or (ii) upon a Change of Control. 
 4. Co-Sale Rights. 
 4.1. Notice of Sales. Should any of the Management Stockholders propose to accept one or more bona fide offers (collectively, a
“Purchase Offer”) from any persons to purchase Shares (the “Management Offered Shares”) from such Stockholder (other than as set forth in Section 4.5), after complying with the terms of Section 2, such
Management Stockholder shall promptly deliver a notice (the “Notice of Sale”) to the Company and each Participating Holder and New Holder stating the terms and conditions of such Purchase Offer including, without limitation, the
number of Management Offered Shares proposed to be sold or transferred, the nature of such sale or transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee. 
  

 7 

 4.2. Exercise of Right. Each Participating Holder and New Holder shall have the right (the
“Co-Sale Right”), exercisable upon written notice to the Company and the selling Management Stockholder within 15 business days of receipt of a Notice of Sale, to participate in the sale of Management Offered Shares pursuant to the
terms and conditions set forth in the Notice of Sale. To the extent a Participating Holder or New Holder exercises such Co-Sale Right in accordance with the terms and conditions set forth below, the number of Management Offered Shares which such
Management Stockholder may sell pursuant to such Purchase Offer shall be correspondingly reduced. The Co-Sale Right of each Participating Holder and New Holder shall be subject to the following terms and conditions: 
 (a) Calculation of Shares. Each Participating Holder or New Holder may sell all or any part of that number of shares of Common Stock issued
or then issuable upon conversion of the then-outstanding shares of the Preferred Stock (“Conversion Stock”), Common Stock received in connection with any stock dividend, stock split or other reclassification thereof, or Common Stock
otherwise issued by the Company and held by the Participating Holder or New Holder (together with the Conversion Stock and Common Stock received in connection with any stock dividend, stock split or other reclassification, “Co-Sale Eligible
Stock”) equal to the product obtained by multiplying (i) the aggregate number of Management Offered Shares covered by the Purchase Offer by (ii) a fraction, the numerator of which is the number of shares of Co-Sale Eligible Stock
at the time owned by such Participating Holder or New Holder and the denominator of which is the sum of (A) the total number of shares of Co-Sale Eligible Stock at the time owned by all Participating Holders and New Holders participating in
such sale plus (B) the total number of Management Offered Shares at the time owned by the selling Management Stockholder. 
 (b)
Delivery of Certificates. Each Participating Holder or New Holder may effect its participation in a sale under this Section 4 by delivering to the selling Management Stockholder for transfer to the prospective purchaser one or
more certificates, properly endorsed for transfer, which represent Co-Sale Eligible Stock which such Participating Holder or New Holder elects to sell. 
 (c) Expenses. The parties hereto acknowledge that each such party shall bear all costs and expenses incurred by such party in connection with the sale of Management Offered Shares or Co-Sale Eligible
Stock pursuant to this Section 4. 
 4.3. Transfer. The stock certificate or certificates that the Participating Holder or
New Holder delivers to the selling Management Stockholder pursuant to Section 4.2 shall be delivered by such Management Stockholder to the prospective purchaser in consummation of the sale pursuant to the terms and conditions specified in the
Notice of Sale, and such Management Stockholder shall within two business days of such sale remit to such Participating Holder or New Holder that portion of the sale proceeds to which such Participating Holder or New Holder is entitled by reason of
its participation in such sale. To the extent that any prospective purchaser or purchasers prohibits such assignment or otherwise refuses to purchase Co-Sale Eligible Stock from a 

  

 8 

 
Participating Holder or New Holder exercising its Co-Sale Right hereunder, the selling Management Stockholder shall not sell to such prospective purchaser or
purchasers any Management Offered Shares unless and until, simultaneously with such sale, the selling Management Stockholder shall purchase such Co-Sale Eligible Stock from such Participating Holder or New Holder for the same consideration and on
the same terms and conditions as the proposed transfer described in the Notice of Sale (which terms and conditions shall be no less favorable than those governing the sale to the purchaser by the Management Stockholder). 
 4.4. No Adverse Effect. The exercise or non-exercise of the rights of the Participating Holders and New Holders hereunder to participate in
one or more sales made by a Management Stockholder shall not adversely affect their rights to participate in subsequent sales by a Management Stockholder. 
 4.5. Permitted Transactions. The provisions of Sections 4.1 through 4.4 shall not apply to: (i) any Transfer by a Management Stockholder of Shares to an Affiliate of such Stockholder; (ii) upon
the death of any Management Stockholder who is a natural person, the distribution of Shares by the will or other instrument taking effect at death of such Stockholder or by applicable laws of descent and distribution to such Stockholder’s
estate, executors, administrators and personal representatives, and then to such Stockholder’s heirs, legatees or distributees, whether or not such recipients are Members of the Immediate Family of such Stockholder; or (iii) any repurchase
by the Company of Common Stock owned by an employee, officer, director, or consultant of the Company at a price that is equal to or less than the original purchase price of such shares in connection with the termination of such person’s
employment or relationship with the Company pursuant to a stock restriction agreement with the Company; provided, that, in all such cases, (x) the Management Stockholder shall provide the Company and the Investors with notice of such
Transfer prior to effecting it, and (y) the transferee shall comply with the requirements of Section 2.7 relating to Permitted Transferees. 
 4.6. Assignment of Rights. The rights of each Participating Holder and New Holder set forth in this Section 4 may be assigned (but only with all related obligations) to any transferee or assignee of
Co-Sale Eligible Stock of such Investor provided that (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to
which such registration rights are being assigned, and (b) such transferee complies with the provisions of Section 2.7 relating to Permitted Transferees. 
 4.7. Termination. 
 (a) Termination Events. The provisions of this
Section 4 shall terminate upon the earliest to occur of any one of the following events (and shall not apply to any transfer by a Management Stockholder in connection with any such event): 
  

	 	(i)	The liquidation, dissolution or cessation of the business operations of the Company; 

  

 9 

	 	(ii)	A Qualified IPO; or 

  

	 	(iii)	A Change of Control. 

 5. Registration Rights. The Investors
shall have the registration rights set forth below. 
 5.1. Definitions. Capitalized terms used but not defined shall have the
meanings ascribed to them in the Series E Stock Purchase Agreement. For purposes of this Agreement: 
 “Commission” means
the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act. 
 “Public
Offering,” or “Offering” means any offering of Common Stock to the public, either on behalf of the Company or any of its security holders, pursuant to an effective registration statement under the Securities Act or any
event causing the Company to have any class of its equity securities registered with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 
 “Registrable Securities” means (i) the Common Stock at any time issued or subject to issuance upon the conversion of the Preferred
Stock, (ii) the Common Stock issued to Medtronic pursuant to the License Agreement dated August 9, 1999, as amended from time to time, by and between the Company and Medtronic (the “License Agreement”) or issued or subject
to issuance upon exercise of the Medtronic Warrants, and (iii) any additional securities issued with respect to the securities described above upon any stock split, stock dividend, recapitalization, or similar event. Registrable Securities
shall cease to be Registrable Securities when (x) a registration statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed of in accordance with such
registration statement, (y) they shall be eligible to be distributed pursuant to Rule 144 promulgated under the Securities Act in a single three month period by the holder thereof or (z) they shall have ceased to be outstanding.

 “Registration Expenses” means the expenses described in Section 5.6. 
 5.2. Demand Registration. 
 (a)
Subject to the provisions of Section 5.2(d) and Section 5.2(e), if at any time after the earlier of four years after the Initial Closing (as defined in the Series E Stock Purchase Agreement) or 180 days after the date the Company first
consummates a Public Offering on Form S-1 or Form SB-2, or any successor forms, the Company shall receive a written request therefor from the record holder or holders of an aggregate of more than 33% of the Registrable Securities (the
“Initiating Holders”), the Company shall prepare and file a registration statement under the Securities Act covering such number of Registrable Securities as are the subject of such request, provided that such Registrable Securities have
an anticipated net aggregate offering price in excess of five million 

  

 10 

 
dollars ($5,000,000), and shall use its best efforts to cause such registration statement to become effective. Upon the receipt of a registration request
meeting the requirements of this Section 5.2(a), the Company shall promptly give written notice to all other record holders of Registrable Securities that such registration is to be effected. The Company shall include in such registration
statement such additional Registrable Securities as such other record holders request within thirty (30) days after the date of the Company’s written notice to them. If (i) the holders of a majority of the Registrable Securities for
which registration has been requested pursuant to this Section 5.2(a) and the holders of a majority of the shares of Registrable Securities held by the Initiating Holders determine for any reason not to proceed with the registration at any time
before the related registration statement has been declared effective by the Commission, (ii) such registration statement, if theretofore filed with the Commission, is withdrawn and (iii) the holders of the Registrable Securities subject
to such registration statement agree to bear their own Registration Expenses incurred in connection therewith and to reimburse the Company for the Registration Expenses incurred by it in such connection or if such registration statement, if
theretofore filed with the Commission, is withdrawn at the initiative of the Company, then the holders of the Registrable Securities shall not be deemed to have exercised one of their two demand registration rights pursuant to this
Section 5.2(a); provided, however, that the holders of Registrable Securities requesting registration shall not be required to reimburse the Company for the Registration Expenses incurred by it in connection with a registration
withdrawn at the request of such holders, and the Company shall not be deemed to have prepared, filed or caused to be effective the registration within the meaning of Section 5.2(c), if the holders requesting withdrawal of the registration do
so in good faith because of material adverse information regarding the Company of which they became aware after requesting registration. 
 (b) At the request of the holders of a majority of the Registrable Securities to be registered, the method of disposition of all Registrable Securities included in a registration under Section 5.2(a) shall be an underwritten offering.
The managing underwriter of any such offering shall be selected by the holders of a majority of the Registrable Securities for which registration has been requested and shall be reasonably acceptable to the Company. If in the good faith judgment of
the managing underwriter of the Public Offering, the inclusion of all of the Registrable Securities the registration of which has been requested would interfere with their successful marketing, the number of Registrable Securities to be included in
the offering shall be reduced, pro rata, among the requesting holders thereof in proportion to the number of Registrable Securities included in their respective requests for registration. Neither the Company nor any holder of
securities (other than Registrable Securities) of the Company shall have the right to include any securities in a registration statement to be filed as part of a demand registration pursuant to this Section 5.2(a) or Section 5.4 unless
(i) such securities are of the same class as the Registrable Securities to be included in the registration (or another class of securities to be sold by the Company for its own account), (ii) the holders of a majority of the Registrable
Securities to be registered consent to such inclusion in writing, (iii) if such registration is an underwritten offering, the Company and such other holders agree in writing to sell their securities on the same terms and conditions as apply to
the Registrable Securities being sold pursuant to the request for registration and (iv) the inclusion of such securities will not, in the judgment of any managing underwriter of the Offering, interfere with the successful marketing of the
Registrable Securities. 
  

 11 

 (c) The Company shall be obligated to prepare, file and cause to be effective only two registration
statements pursuant to Section 5.2(a). 
 (d) Notwithstanding the foregoing, the Company may delay initiating the preparation and
filing of any registration statement requested pursuant to Section 5.2(a) for a period not to exceed one hundred twenty (120) days if (i) in the good faith judgment of the Company’s Board of Directors effecting the registration
would substantially interfere with any material transaction being considered at the time of receipt of the request from the Initiating Holders or (ii) a request for registration is received during the period starting with the date sixty
(60) days prior to the Company’s good faith estimate of the date of the filing of, and ending on a date one hundred eighty (180) days following the effective date of, a Company-initiated registration as to which holders of Registrable
Securities may include Registrable Securities pursuant to Section 5.3 below, provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective and provided further that
such right under subsection (i) to delay a request shall be exercised by the Company not more than once in any 12-month period. 
 (e)
Notwithstanding anything to the contrary contained herein, and without limitation as to the rights of the Company to include in a demand registration securities for sale for its own account as provided in Section 5.2(a), at any time within
thirty (30) days after receiving a demand for registration, the Company may elect to effect an underwritten primary registration in lieu of the requested registration. If the Company so elects, the Company shall give prompt written notice to
all holders of Registrable Securities of its intention to effect such a registration and shall afford such holders the rights contained in Section 5.3 with respect to “piggyback” registrations. In such event, the demand for
registration shall be deemed to have been withdrawn without reducing the number of demand registrations remaining available under Section 5.2(c). 
 5.3. Piggyback Registration. 
 (a) Each time the Company shall determine to proceed with the
actual preparation and filing of a registration statement under the Securities Act in connection with the proposed offer and sale for money of any of its securities by it or any of its security holders (other than a registration statement on Form
S-1 in connection with an initial Public Offering of the Common Stock, Form S-8, Form S-4, or other similar form then in effect solely for registration of securities in connection with an employee benefit plan or dividend reinvestment plan or a
merger, consolidation or acquisition), the Company will give written notice of its determination to all record holders of Registrable Securities. Upon the written request of a record holder of any shares of Registrable Securities given within 30
days after the date of mailing of any such notice from the Company, the Company will, except as herein provided, cause all the Registrable Securities the registration of which is requested to be included in such registration statement, all to the
extent requisite to permit the sale or other disposition by the prospective seller or sellers of the Registrable Securities to be so registered; provided, however, that nothing herein shall prevent the Company from, at any time,
abandoning or delaying any registration; and provided, further, that if the Company determines not to proceed with a registration after the registration statement has been filed with the Commission and the Company’s decision not
to proceed is primarily based upon the anticipated Public 

  

 12 

 
Offering price of the securities to be sold by the Company, then, upon the election by the holders of at least a majority of the Registrable Securities then
outstanding, the Company shall promptly complete the registration for the benefit of those selling security holders who wish to proceed with a Public Offering of their Registrable Securities and who bear all of the Registration Expenses in excess of
$25,000 incurred by the Company as the result of such registration after the Company has decided not to proceed. In the discretion of the holders of the Registrable Securities to be included in the registration (provided that such holders are the
record holders of at least 51% of the Registrable Securities), such registration may count as a demand registration under Section 5.2 (if it otherwise meets the requirements of Section 5.2(a)) for which the Company will pay the
Registration Expenses. 
 (b) If any registration pursuant to this Section 5.3 is underwritten in whole or in part, the Company may
require that the Registrable Securities included in the registration be included in the underwriting on the same terms and conditions as the securities otherwise being sold through the underwriters. If, in the good faith judgment of the managing
underwriter of the Public Offering, the inclusion of all of the Registrable Securities originally covered by requests for registration would reduce the number of shares to be offered by the Company or interfere with the successful marketing of the
shares offered by the Company, the number of Registrable Securities to be included in the Offering may be reduced in the following manner: first, securities held by officers and directors of the Company (other than Registrable Securities)
shall be excluded from such underwritten Public Offering to the extent required by the managing underwriter, second, any securities, other than Registrable Securities, proposed to be sold in the Offering by persons other than the Company
shall be excluded and third, if a further reduction in the Offering is required, the Registrable Securities requested to be included in the Offering shall be reduced, pro rata, among the requesting holders thereof in proportion to the
number of Registrable Securities included in their respective requests for registration. 
 5.4. Short Form Registration. In
addition to the registration rights provided in Sections 5.2 and 5.3, if the Company qualifies for the use of Form S-3 (or any similar registration form), the Company shall at the request of holders of Registrable Securities from time to time
register Registrable Securities on behalf of such holder or holders on such form; provided, however, that the Company shall not be required to effect any such registration pursuant to this Section 5.4 if the holders of Registrable
Securities, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any
underwriters’ discounts or commissions) of less than $5,000,000, unless the Registrable Securities proposed to be included in such registration constitute all of the Registrable Securities held by such holders and have an aggregate price to the
public of more than $1,000,000. The Company shall be obligated to prepare, file and cause to be effective no more than two registration statements pursuant to this Section 5.4 per calendar year. The Company shall give notice of any
proposed Form S-3 registration to the record holders of Registrable Securities who did not join in the request therefor and afford them a reasonable opportunity to do so. Registration effected pursuant to this Section 5.4 shall not be counted
as demands for registration or registrations effected pursuant to Section 5.2. 
  

 13 

 5.5. Registration Procedures. If and whenever the Company is required by the provisions of
Sections 5.2, 5.3 or 5.4 to effect the registration of shares of Registrable Securities under the Securities Act, the Company will use its best efforts to effect the registration and sale of such Registrable Securities in accordance with the
intended methods of disposition specified by the holders participating therein. Without limiting the foregoing, the Company in each such case will, as expeditiously as possible: 
 (a) prepare and file with the Commission (in the case of a demand registration pursuant to Section 5.2 or 5.4) the requisite registration statement
to effect such registration (including such audited financial statements as may be required by the Securities Act or the rules and regulations promulgated thereunder) and use its best efforts to cause such registration statement to become effective;
provided, however, that as far in advance as practical before filing such registration statement or any amendment thereto, the Company will furnish to counsel for the requesting holders copies of reasonably complete drafts of all such
documents proposed to be filed (including exhibits), and any such holder shall have the opportunity to object to any information pertaining solely to such holder that is contained therein and the Company will make the corrections reasonably
requested by such holder with respect to such information prior to filing any such registration statement or amendment; 
 (b) prepare and
file with the Commission such amendments and supplements to such registration statement and any prospectus used in connection therewith as may be necessary to maintain the effectiveness of such registration statement and to comply with the
provisions of the Securities Act with respect to the disposition of all Registrable Securities included in such registration statement, in accordance with the intended methods of disposition thereof, until the earlier of (i) such time as all of
such securities have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof set forth in such registration statement and (ii) one hundred eighty (180) days after such registration statement
becomes effective; 
 (c) promptly notify each requesting holder and the underwriter or underwriters, if any: 
  

	 	(i)	when such registration statement or any prospectus used in connection therewith, or any amendment or supplement thereto, has been filed and, with respect to such registration
statement or any post-effective amendment thereto, when the same has become effective; 

  

	 	(ii)	of any written request by the Commission for amendments or supplements to such registration statement or prospectus; 

  

	 	(iii)	of the notification to the Company by the Commission of its initiation of any proceeding with respect to the issuance by the Commission of, or of the issuance by the Commission of,
any stop order suspending the effectiveness of such registration statement; and 

  

 14 

	 	(iv)	of the receipt by the Company of any notification with respect to the suspension of the qualification of any Registrable Securities for sale under the applicable securities or blue
sky laws of any jurisdiction; 

 (d) furnish to each seller of Registrable Securities included in such registration statement
such number of conformed copies of such registration statement and of each amendment and supplement thereto such number of copies of the prospectus contained in such registration statement (including each preliminary prospectus and any summary
prospectus) and any other prospectus filed under Rule 424 promulgated under the Securities Act relating to such seller’s Registrable Securities, and such other documents as such seller may reasonably request to facilitate the disposition of its
Registrable Securities; 
 (e) use its best efforts to register or qualify all Registrable Securities included in such registration
statement under such other securities or blue sky laws of such jurisdictions as each holder of Registrable Securities thereof shall reasonably request within twenty (20) days following the original filing of such registration statement and to
keep such registration or qualification in effect for so long as such registration statement remains in effect, and take any other action which may be reasonably necessary or advisable to enable such holder to consummate the disposition in such
jurisdictions of the Registrable Securities owned by such holder, except that the Company shall not for any such purpose be required (i) to qualify generally to do business as a foreign corporation in any jurisdiction wherein it would not but
for the requirements of this paragraph (e) be obligated to be so qualified, (ii) to consent to general service of process in any such jurisdiction or (iii) to subject itself to taxation in any such jurisdiction by reason of such
registration or qualification; 
 (f) use its best efforts to cause all Registrable Securities included in such registration statement to be
registered with or approved by such other governmental agencies or authorities as may be necessary to enable each holder thereof to consummate the disposition of such Registrable Securities; 
 (g) if and to the extent any of the following are obtained by or furnished to the Company or the underwriters, furnish to any holder who so requests a
signed counterpart, addressed to such holder (and the underwriters, if any), of: 
  

	 	(i)	an opinion of counsel for the Company, dated the effective date of such registration statement (or, if such registration includes an underwritten Public Offering, dated the date of
any closing under the underwriting agreement), and 

  

	 	(ii)	a “cold comfort” letter, dated the effective date of such registration statement (and, if such registration includes an underwritten Public Offering, dated the date of any
closing under the underwriting agreement), signed by the independent public accountants who have certified the Company’s financial statements included in such registration statement; provided, however, that the obligation to
furnish a “cold comfort” letter shall only be imposed to the extent permitted under any then-prevailing rules of accounting procedure; 

  

 15 

 (h) notify each holder whose Registrable Securities are included in such registration statement, at any
time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event as a result of which any prospectus included in such registration statement, as then in effect, includes an untrue statement
of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and at the request of any such holder
promptly prepare and furnish to such holder a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such securities, such prospectus shall not
include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; 
 (i) otherwise use its best efforts to comply with all applicable rules and regulations of the Commission; 
 (j) provide a transfer agent and registrar for all Registrable Securities included in such registration statement not later than the effective date of
such registration statement; and 
 (k) use its best efforts to cause all Registrable Securities included in such registration statement to
be listed, upon official notice of issuance, on any securities exchange or quotation system on which any of the securities of the same class as the Registrable Securities are then listed. 
 (l) The Company may require each holder whose Registrable Securities are being registered to, and each such holder shall, as a condition to including
Registrable Securities in such registration, furnish the Company and the underwriters with such information and affidavits regarding such holder and the distribution of such securities as the Company and the underwriters may from time to time
reasonably request in writing in connection with such registration. At any time during the effectiveness of any registration statement covering Registrable Securities offered by a holder, if such holder becomes aware of any change materially
affecting the accuracy of the information contained in such registration statement or the prospectus (as then amended or supplemented) relating to such holder, it will immediately notify the Company of such change. 
 (m) Upon receipt of any notice from the Company of the happening of any event of the kind described in paragraph (h) of this Section 5.5, each
holder will forthwith discontinue such holder’s disposition of Registrable Securities pursuant to the registration statement relating to such Registrable Securities until such holder receives the copies of the supplemented or amended prospectus
contemplated by paragraph (h) of this Section 5.5 and, if so directed by the Company, shall deliver to the Company all copies, other than permanent file copies, then in such holder’s possession of the prospectus relating to such
Registrable Securities current at the time of receipt of such notice. 
  

 16 

 5.6. Expenses. With respect to any registration requested pursuant to Section 5.2
(except as otherwise provided in such Section with respect to a registration voluntarily terminated at the request of the requesting holders of Registrable Securities), Section 5.3 (except as otherwise provided in such Section with respect to a
registration continued by selling security holders who wish to proceed with a Public Offering that is withdrawn by the Company) or Section 5.4, the Company shall bear all of the expenses (“Registration Expenses”) incident to
the Company’s performance of or compliance with its obligations under this Agreement in connection with such registration including, without limitation, all registration, filing, securities exchange listing and NASD fees, all registration,
filing, qualification and other fees and expenses or complying with securities or blue sky laws, all word processing, duplicating and printing expenses, messenger and delivery expenses, the fees and disbursements of counsel for the Company and of
its independent public accountants, including the expenses of any special audits or “cold comfort” letters required by or incident to such performance and compliance, premiums and other costs of any policies of insurance against
liabilities arising out of the Public Offering of the Registrable Securities being registered obtained by the Company (it being understood that the Company shall have no obligation to obtain such insurance), and any fees and disbursements of
underwriters customarily paid by issuers or sellers of securities and reasonable fees and disbursements of one counsel for the holders of the Registrable Securities, but excluding underwriting discounts and commissions and transfer taxes, if any, in
respect of Registrable Securities, which discounts, commissions and taxes in respect of Registrable Securities shall in any registration be payable by the holders of the Registrable Securities being registered, pro rata in proportion to the
number of Registrable Securities being sold by them. 
 5.7. Delay of Registration. No holder of Registrable Securities shall
have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 5. 
 5.8. Indemnification. 
 (a)
The Company shall, to the fullest extent permitted by law, indemnify and hold harmless each holder of Registrable Securities which are included in a registration statement pursuant to the provisions of this Section 5 and its directors, officers
and partners and each other person, if any, who controls such holder within the meaning of the Securities Act from and against any and all losses, claims, damages, expenses or liabilities, joint or several (collectively, “Losses”)
to which such holder or any such director, officer, partner or controlling person may become subject under the Securities Act or otherwise, insofar as such Losses (or actions or proceedings, whether commenced or threatened, in respect thereof) arise
out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in a registration statement prepared and filed hereunder, any preliminary, final or summary prospectus contained therein or any amendment or
supplement thereto or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus, in light of the circumstances in which they were made)
not misleading and the Company will reimburse the holder and each such director, officer, partner and controlling person for any legal or other expenses reasonably incurred by them in connection 

  

 17 

 
with investigating or defending against any such Losses (or action or proceeding in respect thereof); provided, however, that the Company will not be
liable in any such case to the extent that any such Losses arise out of or are based upon (i) an untrue statement or alleged untrue statement or omission or alleged omission made in conformity with written information furnished by such holder
specifically for use in the preparation of the registration statement or (ii) such holder’s failure to send or give a copy of the final prospectus to the persons asserting an untrue statement or alleged untrue statement or omission or
alleged omission at or prior to the written confirmation of the sale of Registrable Securities to such person if such statement or omission was corrected in such final prospectus. Such indemnity shall remain in full force and effect regardless of
any investigation made by or on behalf of such holder or any such director, officer, partner or controlling person of such holder and shall survive the transfer of such securities by such holder. The Company shall also indemnify each other person
who participates (including as an underwriter) in the offering or sale of Registrable Securities, their officers and directors, and partners, and each other person, if any, who controls any such participating person within the meaning of the
Securities Act to the same extent as provided above with respect to holders of Registrable Securities. 
 (b) Each holder of shares of
Registrable Securities which are included in a registration pursuant to the provisions of this Section 5 shall, to the full extent permitted by law, indemnify and hold harmless the Company, its officers, directors and each other person, if any,
who controls the Company within the meaning of the Securities Act from and against any and all Losses to which the Company or any such officer, director or controlling person may become subject under the Securities Act or otherwise, insofar as such
Losses (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon any untrue or alleged untrue statement of any material fact contained in a registration statement prepared and filed hereunder,
any preliminary, final or summary prospectus contained therein or any amendment or supplement thereto, or arise out of or are based upon the omission or the alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein (in the case of a prospectus, in the light of the circumstances under which they were made) not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or
omission or alleged omission was so made in reliance upon and in strict conformity with written information furnished by such holder specifically for use in the preparation of such registration statement. Such indemnity shall remain in full force
and effect regardless of any investigation made by or on behalf of the Company or any such director, officer or controlling person of the Company. The holder of Registrable Securities included in a registration statement shall also indemnify each
other person who participates (including as an underwriter) in the offering or sale of Registrable Securities, their officers and directors, and partners, and each other person, if any, who controls any such participating person within the meaning
of the Securities Act to the same extent as provided above with respect to the Company. In no event shall the liability of any holder under this Section 5.8(b) exceed the net proceeds received by such holder from the sale of their Registrable
Securities. Each holder under this Section 5.8 shall be severally, not jointly, liable. 
 (c) Promptly after receipt by an indemnified
party pursuant to the provisions of paragraph (a) or (b) of this Section 5.8 of notice of the commencement of any action involving the subject matter of the foregoing indemnity provisions, such indemnified party will, if a claim
thereof is to be made against the indemnifying party pursuant to the provisions of paragraph (a) or 

  

 18 

 
(b), promptly notify the indemnifying party of the commencement thereof; but the omission to so notify the indemnifying party will not relieve the
indemnifying party from any liability which it may have to any indemnified party except to the extent that the indemnifying party is actually prejudiced by such failure to give notice. In case any such action is brought against any indemnified
party, the indemnifying party shall have the right to participate in, and, to the extent that it may wish, jointly with any other indemnifying party, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party;
provided, however, that if the defendants in any action include both the indemnified party and the indemnifying party and the indemnified party reasonably concludes that there is a conflict of interest that would prevent counsel for
the indemnifying party from also representing the indemnified party, the indemnified party shall have the right to select separate counsel to participate in the defense of such action on behalf of the indemnified party or parties. After notice from
the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party pursuant to the provisions of said paragraph (a) or (b) for any legal or
other expense subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed counsel in accordance with the proviso of the preceding sentence, (ii) the
indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after the notice of the commencement of the action or (iii) the indemnifying party
has authorized the employment of counsel for the indemnified party at the expense of the indemnifying party. If the indemnifying party is not entitled to, or elects not to, assume the defense of a claim, it will not be obligated to pay the fees and
expenses of more than one counsel for the indemnified parties with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other indemnified parties
with respect to such claim, in which event the indemnifying party shall be obligated to pay the fees and expenses of additional counsel or counsels for the indemnified parties. No indemnifying party shall consent to entry of any judgment or enter
into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation without the consent of the
indemnified party. No indemnifying party shall be subject to any liability for any settlement made without its consent. An indemnified party may at any time elect to participate in the defense of any claim or proceeding at its own expense.

 (d) If the indemnification provided for in this Section 5 is held by a court of competent jurisdiction to be unavailable or
insufficient to hold harmless an indemnified party, then each indemnifying party shall contribute to the amount paid or payable to such indemnified party as a result of the Losses an amount or additional amount, as the case may be, in such
proportion as is appropriate to reflect the relative fault of the indemnifying party or parties on the one hand and the indemnified party on the other in connection with the statements or omissions which resulted in such Losses as well as any other
relevant equitable considerations. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to
information supplied by the indemnifying party or parties on the one hand or the indemnified party on the other and the parties’ relative, intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or
omission. The amount paid to an indemnified party as a result of the Losses referred to 

  

 19 

 
in the first sentence of this Section 5.8(d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating or defending any action or claim which is the subject of this Section 5.8. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. Nothwithstanding the foregoing or anything else herein to the contrary, in no event shall any holder of Registrable Securities be required to contribute an amount
that exceeds the net proceeds received by such holder from the sale of their Registrable Securities. 
 (e) Notwithstanding the foregoing,
to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten Public Offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control. 
 (f) The obligations of the Company and holders of Registrable Securities under this
Section 5.8 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 5, and otherwise. 
 5.9. Covenants Relating to Rule 144. If at any time the Company is required to file reports in compliance with either Section 13 or Section 15(d) of the Exchange Act, the Company will
(a) file reports in compliance with the Exchange Act and (b) comply with all rules and regulations of the Commission applicable to the use of Rule 144. 
 5.10. Underwritten Offerings. If a distribution of Registrable Securities pursuant to a registration statement is to be underwritten, the holders whose Registrable Securities are to be distributed by
such underwriters shall be parties to such underwriting agreement. No requesting holder may participate in such underwritten offering unless such holder agrees to sell its Registrable Securities on the basis provided in such underwriting agreement
and completes and executes all questionnaires, powers of attorney, indemnities and other documents reasonably required under the terms of such underwriting agreement. If any requesting holder disapproves of the terms of an underwriting, such holder
may elect to withdraw therefrom and from such registration by notice to the Company and the managing underwriter, and each of the remaining requesting holders shall be entitled to increase the number of Registrable Securities being registered to the
extent of the Registrable Securities so withdrawn in the proportion which the number of Registrable Securities being registered by such remaining requesting holder bears to the total number of Registrable Securities being registered by all such
remaining requesting holders. 
 5.11. Stand-Off Agreement. Each holder of Registrable Securities agrees, in connection with
the Company’s initial Public Offering and any other underwritten Public Offering, upon request of the Company or the underwriters managing such Offering, not to sell, make any short sale of, loan, grant any option for the purchase of, or
otherwise dispose of any shares of Common Stock of the Company other than those included in the registration without the prior written consent of such underwriters for such period of time (not exceeding 180 days in the case of the Company’s
initial Public Offering and 90 days in the case of any other underwritten Public 

  

 20 

 
Offering) from the effective date of such registration as may be requested by the underwriters; provided, however, that all of the Affiliates,
officers, directors and employees of the Company who own stock of the Company and holders of at least 1% of the Company’s voting securities must also agree to not less onerous restrictions. 
 5.12. Amendment of Registration Rights. Without the written consent of the holders of at least a majority of the then-outstanding
Registrable Securities, the Company shall not amend this Section 5, or enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder to include such
securities as Registrable Securities under this Section 5. Any amendment to this Section 5 pertaining only to rights of a particular class or series of the Company’s outstanding capital stock and affecting such rights adversely and in
a manner materially different from its effect on the rights of the other outstanding class or series of the Company’s outstanding capital stock must be approved by the holders of at least 66 2/3% of the outstanding shares of such class or
series of capital stock. 
 5.13. Termination. This Section 5, and all of the Company’s obligations (other than its
obligations pursuant to Section 5.8, which Section shall survive such termination) under this Section 5, shall terminate upon the earlier to occur of (i) the date on which there are no Registrable Securities outstanding and
(ii) the fifth anniversary of the effective date of the registration statement filed with respect to the Company’s initial Public Offering. 
 5.14. Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Section 5 may be assigned (but only with all related obligations) by a
holder of Registrable Securities to a transferee or assignee of such securities that (i) is an Affiliate, partner, limited partner, retired partner, holder of limited liability company interest, or shareholder of such holder, (ii) is a
Member of the Immediate Family of such holder, or (iii) after such assignment or transfer, holds at least 250,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations and other
recapitalizations), provided: (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration
rights are being assigned; and (b) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including without limitation the provisions of Section 5.11 above. 
 5.15. Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the holders of a majority of the Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder (a) to include such
securities in any registration filed under Section 5.3, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities
will not reduce the amount of the Registrable Securities of the Holders that are included or (b) to demand registration of their securities. 
  

 21 

 6. Covenants of the Company. The Company covenants and agrees that: 
 6.1. Corporate Existence. The Company will maintain its corporate existence in good standing. 
 6.2. Books of Account and Reserves. The Company will keep, and will cause any of its subsidiaries to keep, books of record and account in
which full, true and correct entries are made of all of its and their respective dealings, business and affairs, in accordance with generally accepted accounting principles. When so requested by the Investors, the Company will employ certified
public accountants who are “independent” within the meaning of the accounting regulations of the Commission and who are approved by the Investors. At such time, the Company will have annual audits made by such independent public
accountants in the course of which such accountants shall make such examinations, in accordance with generally accepted auditing standards, as will enable them to give such reports or opinions with respect to the financial statements of the Company
and its subsidiaries as will satisfy the requirements of the Commission in effect at such time with respect to reports or opinions of accountants. At such time as independent public accountants are employed by the Company, management will request
such independent public accountants to issue to the Company a management letter of recommendations in connection with each annual audit of the financial statements of the Company. In the event the services of the independent public accountants are
terminated, the Company will promptly notify the Investors of such termination and will request such independent public accountants to send a letter to the Investors advising them in the detail requested by the Investors of the reasons for the
termination of their services. 
 6.3. Furnishing of Financial Statements and Information. The Company will deliver to each
Investor that continues to hold Preferred Stock: 
 (a) within five days of their availability, but in any event within 45 days after the end
of the first three quarters in each fiscal year of the Company, the unaudited consolidated balance sheets of the Company and its subsidiaries as of the end of such quarter and the consolidated statements of income and retained earnings and
statements of cash flows for such quarter and the portion of the fiscal year then ended of the Company and its subsidiaries, setting forth in comparable form figures for the comparable period of the previous fiscal year; and 
 (b) within five days of their availability, but in any event within 120 days after the end of each Company fiscal year, the audited consolidated balance
sheet of the Company and its subsidiaries, as of the end of such fiscal year, together with the related consolidated statements of income and retained earnings and statements of cash flows for such fiscal year, setting forth in comparative form
figures for the previous fiscal year, all in reasonable detail and accompanied by the unqualified reports thereon of independent certified public accountants to the effect that such consolidated financial statements have been prepared in accordance
with GAAP and present fairly in all material respects the financial position of the Company and its subsidiaries as of the dates specified and the results of their operations and changes in financial position with respect to the periods specified;
and 
  

 22 

 (c) within five days of their availability, but in any event within 30 days of the end of each month, a
summary financial information for such month. 
 6.4. Inspection. So long as an Investor holds shares of Common Stock or
Preferred Stock, the Company will permit such Participating Holder or New Holder and any of their partners, officers or employees, or any outside representatives designated by such Participating Holder or New Holder and reasonably satisfactory to
the Company, to visit and inspect at the expense of such Participating Holder or New Holder, any of the properties of the Company or its subsidiaries, including their books and records (and to make photocopies thereof or extracts therefrom), and to
discuss their affairs, finances and accounts with their officers, except with respect to trade secrets and similar confidential information unless the Participating Holder or New Holder shall have entered into a confidentiality agreement with the
Company precluding disclosure of such information, all to such reasonable extent and at such reasonable times and intervals as such Participating Holder or New Holder may reasonably request without disruption of the Company’s operations.

 6.5. Payment of Taxes and Maintenance of Property. The Company will, and will cause any of its subsidiaries to: 

(a) pay and discharge promptly, or cause to be paid and discharged promptly when due and payable, all taxes, assessments and governmental charges or
levies imposed upon it or upon its income or upon any of its property, real, personal or mixed, or upon any part thereof, as well as all material claims of any kind (including claims for labor, material and supplies) which, if unpaid, might by law
become a lien or charge upon its property; provided, however, that neither the Company nor any subsidiary shall be required to pay any such tax, assessment, charge, levy or claim while the amount, applicability or validity thereof is being contested
in good faith by appropriate proceedings, provided that the Company or such subsidiary, as the case may be, shall have set aside on its books reserves (segregated to the extent required by generally accepted accounting principles) deemed adequate by
it with respect thereto; and 
 (b) maintain and keep, or cause to be maintained and kept, its properties in good repair, working order and
condition, and from time to time make, or cause to be made, all repairs and renewals and replacements which in the opinion of the Company are necessary and proper so that the business carried on in connection therewith may be properly and
advantageously conducted at all times. 
 6.6. Insurance. The Company will, and will cause each of its subsidiaries to:

 (a) keep or cause all of its insurable property or properties (including valuable papers) to be kept insured against loss or damage
against fire and other risks; 
 (b) maintain general liability insurance against (i) claims for personal injury, death or property
damage suffered by others upon or in or about the premises occupied by it or occurring as a result of its maintenance or operation of any automobiles, trucks or other vehicles or other facilities and (ii) claims for product liability;

  

 23 

 (c) maintain directors’ and officers’ liability insurance on terms reasonably acceptable to the
holders of a majority of the shares of Preferred Stock; 
 (d) maintain in full force and effect keyman life insurance on the Chief Executive
Officer in the amount of $2,000,000, naming the Company as loss payee; and 
 (e) maintain all such worker’s compensation or similar
insurance as may be required under the laws of any state or jurisdiction in which it may be engaged in business. 
 All insurance for which
provision has been made in this Section 6.6 shall be maintained in the amounts and to the extent determined to be reasonable by the Board of Directors of the Company. All such insurance shall be procured and maintained in force under a policy
or policies issued by insurers of recognized responsibility, except that the Company or any subsidiary may procure worker’s compensation or similar insurance in respect of operations in any state or other jurisdiction either through an
insurance fund operated by such state or other jurisdiction or by causing to be maintained a system or systems of self insurance which is in accord with applicable laws. The Company will provide the Investors from time to time upon request with
evidence of the insurance company’s policies then in force. 
 6.7. Payment of Indebtedness and Discharge of Obligations.
The Company will, and will cause any of its subsidiaries to, pay or cause to be paid the principal of and interest and premium, if any, on all indebtedness for borrowed money heretofore or hereafter incurred or assumed by it when and as the same
shall become due and payable, unless such indebtedness for borrowed money is renewed or extended. The Company will, and will cause each of its subsidiaries to, faithfully observe, perform and discharge all of the material covenants, conditions and
obligations which are imposed on it by any and all indentures and other agreements securing or evidencing such indebtedness for borrowed money or pursuant to which such indebtedness for borrowed money is issued, and will not permit the continuance
of any act or omission which is, or under the provisions thereof may be declared to be, a material default thereunder, unless such default is waived pursuant to the provisions thereof. Neither the Company nor any of its subsidiaries shall be
required to make any payment or to take any other action by reason of this Section 6.7 at any time while the Company is contesting in good faith by appropriate proceedings its obligations to make such payment or to take such action, provided
that the Company or such subsidiary, as the case may be, shall have set aside on its books reserves (segregated to the extent required by generally accepted accounting principles) deemed adequate by it with respect thereto. 
 6.8. Preparation and Approval of Budgets. So long as a Participating Holder or New Holder holds shares of Common Stock or Preferred Stock,
at least one month prior to the beginning of each fiscal year of the Company, the Company shall prepare and submit to its Board of Directors for discussion purposes a first draft of an annual plan for such year which shall include monthly capital
and operating expense budgets, cash flow statements and profit and loss projections and year-end projected balance sheets, itemized in such detail as the Board of Directors may reasonably request. The final draft of such annual plan shall be
presented to the Board of Directors of the Company for approval prior to the beginning of each fiscal year of the Company and, after such annual plan is approved by the Board of Directors, a summary of such annual plan (such summary to be approved
by the Board of Directors) shall 

  

 24 

 
be furnished to the Investors holding shares of Common Stock or Preferred Stock. Each annual plan shall be modified as often as is necessary to reflect
changes required as a result of operating results and other events that occur, or may be reasonably expected to occur, during the year covered by the annual plan, and copies of such modification shall be submitted to the Board of Directors of the
Company. 
 6.9. Replacement of Stock Certificates. Any Stockholder claiming the loss, theft, destruction or mutilation of any
certificate representing Common Stock, Preferred Stock or Conversion Stock may be issued a new certificate in accordance with the requirements of the Bylaws of the Company. 
 6.10. Indemnification Bylaw. The Bylaws of the Company will at all times contain a section requiring the Company to indemnify its officers
and directors to the fullest extent permitted by the Delaware General Corporation Law. 
 6.11. Employee Agreements. The
Company shall use best efforts to cause each of its key officers and employees to execute a confidentiality and assignment of inventions agreement. The Company shall use best efforts to cause each of its key executives to execute a non-compete
agreement. 
 6.12. Directors Expenses; Meetings. The Company shall reimburse the designees of the Investors to the Board of
Directors for reasonable expenses including, without limitation, travel and lodging expenses incurred in attending meetings of the Board of Directors (and any meetings of committees thereof) and any other meetings or events attended at the request
of the Company. The Company shall hold meetings of the Board of Directors at least once every calendar quarter unless waived by a majority of directors designated by the Investors. 
 6.13. Qualified Small Business Stock. The Company will use its best efforts to comply with any reporting and record keeping requirements of
Section 1202 of the Internal Revenue Code of 1986, as amended, and of any regulations promulgated thereunder, and agrees not to repurchase any stock of the Company if such repurchase would cause the Preferred Stock or the Common Stock issued
upon conversion of the Preferred Stock not to so qualify as “Qualified Small Business Stock.” To the extent that the Preferred Stock or the Common Stock issued upon conversion of the Preferred Stock ceases to qualify as Qualified Small
Business Stock, any further obligations thereafter under this Section 6.13 shall immediately terminate. 
 6.14.
Termination. The Company’s obligations under this Section 6 shall terminate and this Section 6 shall be of no further force and effect (i) upon the consummation of Qualified IPO or (ii) upon a Change of
Control. 
 7. Board of Directors. 
 7.1. Designation of Director. The Stockholders agree to vote all of the Company’s Common Stock, Preferred Stock and any other voting securities of the Company now owned or hereafter acquired or controlled by them, and
otherwise use their respective best efforts as stockholders or directors of the Company, to cause and maintain the election to the Board of Directors of the Chief 

  

 25 

 
Executive Officer of the Company. The remaining directors shall be elected by the stockholders of the Company pursuant to the provisions of the Amended and
Restated Certificate of Incorporation and Bylaws of the Company. 
 7.2. Termination. The provisions of this Section 7
shall terminate and be of no further force and effect (i) upon the consummation of a Qualified IPO or (ii) upon a Change of Control. 
 8.
Miscellaneous. 
 8.1. Legended Certificates. Each certificate representing Shares shall bear the following
legend: 
 THE SHARES OF STOCK REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN TRANSFER RESTRICTIONS AS SET FORTH IN AN AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT DATED AS OF FEBRUARY 12, 2007, A COPY OF WHICH IS ON FILE IN THE OFFICES OF THE CORPORATION AND WILL BE FURNISHED TO THE HOLDER HEREOF WITHOUT CHARGE UPON WRITTEN REQUEST. 
 8.2. Successors and Assigns. Except as otherwise provided in this Agreement, the terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and
assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 8.3. Amendments and Waivers. This Agreement may not be orally amended, modified, extended or terminated, nor shall any oral waiver of any of its terms be effective. In addition to any additional approvals expressly required by
this Agreement, this Agreement may be amended, modified, extended or terminated, and the provisions hereof may be waived, by an agreement in writing signed by the holders of a majority or more of the voting power of all Shares then held by the
Investors, voting together as a single class (provided that such amendment, modification, extension, termination or waiver shall affect all holders of Shares equally); provided, however, that (a) the consent of the holders of a
majority or more of the voting power of all Shares then held by the Management Stockholders shall be required for any amendment, modification, extension, termination or waiver which has an adverse effect on the rights of the Management Stockholders
as such under this Agreement, (b) any amendment, modification, extension, termination or waiver to this Agreement pertaining only to rights of a particular class or series of the Company’s outstanding capital stock and affecting such
rights adversely and in a manner materially different from its effect on the rights of the other outstanding class or series of the Company’s outstanding capital stock must be approved by the holders of more than 66 2/3% of the outstanding
shares of such class or series of capital stock, and (c) the Company shall, in each case, deliver copies of such consent in writing to any parties to this Agreement who did not execute the same. Each such amendment, modification, extension,
termination and waiver shall be binding upon each party hereto and each holder of Shares subject hereto. In addition, each party hereto and each holder of Shares subject hereto may waive any right hereunder by an instrument in writing signed by such
party or holder. 
  

 26 

 8.4. Notices. Any notice required or permitted by this Agreement shall be in writing and
shall be deemed sufficient upon delivery, when delivered personally or by overnight courier or sent by telegram or facsimile, or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, addressed to the
party to be notified at such party’s address as set forth on Schedule A and Schedule B to this Agreement as subsequently modified by written notice, and if to the Company, at its principal office to the attention of the Chief
Executive Officer with a copy to Steven A. Wilcox, Ropes & Gray, One International Place, Boston, Massachusetts 02110. 
 8.5.
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable
and enforceable replacement for such provision, then (a) such provision shall be excluded from this Agreement, (b) the balance of this Agreement shall be interpreted as if such provision were so excluded and (c) the balance of this
Agreement shall be enforceable in accordance with its terms. 
 8.6. Governing Law. This Agreement and all acts and
transactions pursuant hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of laws. 
 8.7. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 8.8. Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
 8.9. Aggregation
of Stock. All shares of Preferred Stock held or acquired by Affiliates of an Investor shall be aggregated together for the purpose of determining the availability of any rights of such Investor under this Agreement. 
 8.10. Binding Effect, Etc. Except for restrictions on Transfer of Shares set forth in other agreements, plans or other documents, this
Agreement constitutes the entire agreement of the parties with respect to its subject matter, supersedes all prior or contemporaneous oral or written agreements or discussions with respect to such subject matter (including without limitation the
2003 Investors’ Rights Agreement), and shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, representatives, successors and assigns. 
 8.11. Consent to Jurisdiction. Each party to this Agreement, by his or its execution hereof, (i) hereby irrevocably submits to the
exclusive jurisdiction of the state courts of the State of Delaware or the United States District Court located in the State of Delaware for the purpose of any litigation arising out of or based upon any of the Series E Documents (as defined in the
Series E 

  

 27 

 
Stock Purchase Agreement) or relating to the subject matter thereof, in each case whether now existing or hereafter arising (the “Litigation”),
(ii) hereby waives, to the extent not prohibited by applicable law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such Litigation, any claim that he or it is not subject personally to the jurisdiction of the
above-named courts, that his or its property is exempt or immune from attachment or execution, that any such Litigation brought in one of the above-named courts may be removed to any federal court, should be dismissed on grounds of forum non
conveniens, should be transferred to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that any of the
Series E Documents (as defined above), or the subject matter thereof, whether now existing or hereafter arising, may not be enforced in or by such court, or that any of the Series E Documents (as defined above) or the subject matter thereof may not
be enforced in or by such court and (iii) hereby agrees not to commence any Litigation arising out of or based upon any of the Series E Documents (as defined above) or relating to the subject matter thereof, whether now existing or hereafter
arising, other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such Litigation to any court other than one of the above-named courts whether on
the grounds of inconvenient forum or otherwise. Each party to this Agreement hereby (x) consents to service of process in any such Litigation in any manner permitted by Delaware law; (y) agrees that service of process made in accordance
with clause (x) or by registered or certified mail, return receipt requested, at its address specified pursuant to Section 8.4, is reasonably calculated to give actual notice of any such Litigation; and (z) waives and agrees not to
assert (by way of motion, as a defense, or otherwise) in any such Litigation any claim that service of process made in accordance with clause (x) or (y) does not constitute good and sufficient service of process. 
 8.12. Additional Investors. The Company and the Investors acknowledge and agree that certain additional persons may purchase shares of
Series E Preferred pursuant to the provisions of Section 1.2(c) of the Series E Stock Purchase Agreement and, upon any such person’s purchase of any of such shares and his or its execution of this Agreement, such person shall for all
purposes be considered a “Purchaser” and an “Investor” hereunder. The Company and the Investors acknowledge and agree that, under the terms of Section 1.3(9) of this Agreement, the right of first offer set forth in
Section 1 of this Agreement shall not apply to the issuance of securities to such additional persons pursuant to the Series E Stock Purchase Agreement. 
 8.13. Additional Management Stockholders. The Company shall require each director, officer, key management employee, and key technical employee (and any other person designated by the Board of Directors
of the Company as a Management Stockholder) who purchases shares of the Company’s capital stock or to whom shares of the Company’s capital stock are issued, pursuant to the exercise of an option or otherwise, to execute a counterpart to
this Agreement, whereupon his or her name shall be added to Schedule B and he or she shall be deemed to be a Management Stockholder for purposes of this Agreement. 
  

 28 

 8.14. Additional New Holders. The Company shall require any additional New Holder to
execute a counterpart to this Agreement, whereupon his or her name shall be added to Schedule A and he or she shall be deemed to be a New Holder for purposes of this Agreement. 
 8.15. Horizon Technology. Attached hereto as Exhibit A is the Instrument of Joinder to Amended and Restated Investors’ Rights
Agreement of the Company, dated May 24, 2005, executed by Horizon Technology Funding Company II LLC and Horizon Technology Funding Company III LLC. 
 8.16. Brown Brothers Harriman & Co. For purposes of Section 5.3(b) of this Agreement, all references to “Registrable Securities” in the second sentence of such Section 5.3(b)
shall be deemed to include the shares of Common Stock issued or subject to issuance upon exercise of the Brown Brothers Warrant. 
 [Signature
pages follow] 
  

 29 

 The parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first
written above. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	/s/ M. Jacqueline Eastwood
		 	M. Jacqueline Eastwood
		 	Chief Executive Officer
	
	INVESTORSLicense Agreement between the Registrant and Medtronic

 Exhibit 4.3 
 LICENSE AGREEMENT 
 This License Agreement is made this 9th day of August, 1999 (the “Effective
Date”), by and among Virtuel Medical Devices, Inc. (“Licensee”), a Delaware corporation, and Medtronic, Inc. (“Medtronic”), a Minnesota corporation. 
 RECITALS: 
 A. Medtronic has developed certain technology related to “Wet
Electrode Products” (as defined below) and a “Wet Electrode Generator” (as defined below). 
 B. Medtronic desires to grant,
and Licensee desires to obtain, an exclusive, worldwide royalty-bearing license to the “Subject Technology” (as defined below) in certain fields of use in accordance with all of the terms of this Agreement. 
 NOW, THEREFORE, the parties hereto agree as follows: 
 ARTICLE 1 
 Definitions 
 As used herein, the following definitions and terms shall have the designated meanings: 
 1.1. “Action” shall mean
any claim, action, suit or proceeding, whether civil or criminal, or in law or equity and including any arbitration. 
 1.2.
“Affiliate” of any entity shall mean any other entity that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the first entity. Control shall mean owning at
least 50 percent of the total voting power of the entity. 
 1.3. “Confidential Information” shall mean all information
provided to a party (the “receiving party”) by a party (the “disclosing party”) or its employees, agents or consultants, excluding any information which: 
 (a) is or becomes publicly available through no fault of the receiving party; or 
 (b) can be reasonably demonstrated to have been known to the receiving party independently of any disclosure of “Confidential Information” by
the disclosing party or its employees, agents or consultants; or 
 (c) is disclosed to the receiving party by a third party who, to the best
of the receiving party’s knowledge, is lawfully in possession of the same and has the right to make such disclosure; or 
  
  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 (d) has been independently developed by the receiving party without reference to the information
disclosed to the receiving party by the disclosing party or its employees, agents or consultants. 
 All “Confidential Information” disclosed to
the receiving party under this Agreement shall ultimately be in writing and bear a legend “Proprietary”, “Confidential” or words of similar import. Accordingly, all “Confidential Information” disclosed in any manner
other than writing shall be preceded by an oral statement indicating that the information is proprietary or confidential and shall be followed by transmittal of a reasonably detailed written summary of the information provided to the receiving party
with identification as “Confidential Information” designated as above within thirty (30) days. 
 1.4.
“Expiration” or “Expired” shall mean with respect to a particular patent, the patent’s expiration, abandonment, cancellation, disclaimer, award to another party other than Medtronic or an Affiliate of Medtronic
in an interference proceeding, or declaration of invalidity or unenforceability of all claims thereof by a court or other authority of competent jurisdiction (including a re-examination or reissue proceeding) from which no further appeal has or can
be taken. References to an “Unexpired” patent shall mean a patent that has not Expired. 
 1.5. “Field of Use”
shall mean any [*] applications in [*] (including, but not limited to, [*] during and following [*] other than and hereby expressly excluding applications relating to: (i) the [*] and [*]: (ii) the [*] and [*] and the [*] and [*] and [*]
and [*] and [*] thereof; (iii) the [*], the [*] and the [*] of the [*]; (iv) the [*]; and (v) the [*] when accessed by [*] means. Without limitation of the forgoing, the Field of Use shall also specifically exclude application in the
fields of [*] (excluding [*] of the [*] during and following [*]) and [*]. 
 1.6. “Law” shall mean any law, regulation,
rule, ordinance or governmental regulation or guideline or any judicial, administrative or arbitration, order or award, judgment, writ, injunction or decree which is applicable to a person or by which a person is bound. 
 1.7. “Licensed Products” shall mean Wet Electrode Products and Wet Electrode Generators, the manufacture, use or sale of which uses or
incorporates any of the Subject Technology. 
 1.8. “Net Sales” of Licensed Products for a particular period shall mean the
amounts that Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2 invoices third parties (eliminating transactions between Affiliates) for sales of Licensed Products during such period, excluding sales, use or
excise tax, freight, duty or insurance included therein, and credits or repayments due to rejection, defect or return. If Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2 sells at a single price or rate a
packaged combination of products, not all of which if sold individually would be Licensed Products, then “Net Sales” of Licensed Products with respect to such sales of packaged products shall equal the total sales price of the packaged
combination multiplied by the ratio of the individual retail list price of the Licensed Products contained in the packaged combination to the sum of all individual retail list prices of every item in the packaged combination (if all of such items
were sold separately). If all such items are not sold separately, any item not sold separately shall have a price attributed to it for purposes of this definition consistent with pricing of similar products or their functional equivalents. Without
limitation of the foregoing, Net Sales shall include all transfers of 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 2 

 Licensed Products that Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2 records as
a sale pursuant to generally accepted accounting principles consistently applied. Net Sales which are denominated in currencies other than U.S. Dollars shall be converted into U.S. Dollars on a monthly basis at the average of the applicable daily
exchange rates listed in the Wall Street Journal for the calendar month in which such Net Sales occurred, or on such other basis to which the parties may hereafter mutually agree. 
 1.9. “Product Liability Claims” shall mean claims for personal injury or death based on alleged breach of product warranty, strict
liability in tort, or negligent product design or manufacture. 
 1.10. “Quarter” means each three-month period ending
March 31, June 30, September 30, and December 31. 
 1.11. “Subject Technology” shall mean
(i) the issued patents, and patents arising out of the patent applications, listed on Exhibit A hereto, (ii) all reissues, continuations, continuations-in-part, extensions, reexaminations, and foreign counterparts thereof, (iii) all
invention disclosures, trade secrets and know-how owned by Medtronic prior to the date of this Agreement which relate specifically to the Wet Electrode Products and Wet Electrode Generators disclosed in the patents and the patent applications listed
on Exhibit A, and (iv) those improvements, enhancements and modifications defined in Section 2.6(c). The Subject Technology does not include any trademarks, trade names or service marks owned or used by Medtronic. 
 1.12. “Territory” shall mean the entire world. 
 1.13. “Wet Electrode Generator(s)” shall mean the medical generators primarily intended to provide power directly to Wet Electrode Products, in the Field of Use. 
 1.14. “Wet Electrode Products” shall mean medical blades, forceps or rollerballs that employ an electrode to deliver radio frequency
energy and an electrically conductive fluid between the electrode and the surface of living tissue to apply radio frequency energy in medical applications, in the Field of Use. Wet Electrode Products specifically exclude any interstitial needle or
intraluminal wire devices or products. 
 ARTICLE 2 
 License; Term and Termination 
 2.1. License Grant. Subject to the terms and provisions
hereof, Medtronic hereby grants to Licensee (a) a royalty-bearing, and exclusive license under the Subject Technology to make, have made, use and sell Wet Electrode Products in the Field of Use that are Licensed Products throughout the
Territory and (b) a royalty-bearing and non-exclusive license under the Subject Technology to make, have made, use and sell Wet Electrode Generators in the Field of Use that are Licensed Products throughout the Territory. 
 2.2. Sublicensing and Distribution. Licensee shall have the right to sublicense its rights under Section 2.1 and to enter into distribution,
OEM and other relationships with third parties with respect to the Licensed Products in the Field of Use, provided that 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 3 

 (i) such sublicense or other agreement with a sublicensee or third party or an Affiliate of Licensee (“Other
Agreement”) shall obligate such sublicensee or third party or an Affiliate of Licensee to assume and abide by all duties, obligations and restrictions provided under this Agreement and Licensee shall cause such sublicensee or third party or an
Affiliate of Licensee to comply with all of Licensee’s duties, obligations and restrictions hereunder, (ii) within thirty (30) days of execution of an Other Agreement, Licensee shall provide a copy of such Other Agreement to
Medtronic, (iii) any such sublicense or third party relationship granted by Licensee shall terminate automatically upon the termination of this Agreement, or shall be modified, if applicable, to become non-exclusive if Medtronic exercises its
rights under Section 4.4, and (iv) the royalty rate due from such sublicensee or third party of an Affiliate of Licensee under an Other Agreement shall at no time be less than the royalty rate due Medtronic under Section 3.2 of the
Agreement. Prior to termination, Licensee shall be responsible for: (i) the payment to Medtronic of all royalties based upon the Net Sales of License Products by such sublicensees or such third parties or by Licensee’s Affiliates; and
(ii) the performance of all of the obligations of such sublicensees or such third parties or by Licensee’s Affiliates herein. 
 2.3. Term of License. Unless otherwise terminated under provisions of this Article 2, this Agreement and the licenses granted under Sections 2.1 and 2.2 shall continue until such time as (i) all of the patents (including patents
arising out of the patent applications listed on Exhibit A) included within the Subject Technology (and all extensions thereof) have Expired or (ii) ten (10) years from the first commercial sale of a Licensed Product, whichever is longer.

 2.4. Termination. 
 (a)
If Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2 breaches any of the material terms, conditions or agreements of this Agreement (including failure to restrict sales of Licensed Products and other activities
hereunder to the Field of Use), then Medtronic may terminate this Agreement, at its option and without prejudice to any of its other legal and equitable rights and remedies, including, but not limited to, seeking monetary damages and/or an
injunction, by giving Licensee sixty (60) days notice in writing, particularly specifying the breach. Such notice of termination shall not be effective if Licensee cures the specified breach within such sixty (60) day period. During such
60-day period, one or more executive officers of each party (meaning for purposes hereunder any vice president or higher level officer) shall meet or correspond to discuss such alleged breach and/or attempted cure thereof, and attempt in good faith
to resolve any dispute between the parties with respect thereto; provided that if any such dispute is not resolved to Medtronic’s satisfaction, then Medtronic may terminate this Agreement without prejudice to any of its other legal and
equitable rights and remedies including, but not limited to, seeking monetary damages and/or an injunction. If Licensee cures the breach during the 60-day period but, within one (1) year thereafter, the same or a substantially similar breach
occurs, then the parties shall determine, in good faith, a mutually agreed plan to address the conditions causing such breaches and to avoid or minimize future occurrences of such breach and Licensee thereafter shall use reasonable commercial
efforts to implement such plan, if no such mutual agreement is reached within sixty (60) days of notice of such breach, then Medtronic may terminate this Agreement, at its option and without prejudice to any of its other legal and equitable
rights and remedies, including, but not limited to, 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 4 

 seeking monetary damages and/or an injunction, by giving written notice to Licensee and without providing further
opportunity to cure such breach. Licensee may terminate this Agreement at any time in its discretion upon sixty (60) days’ prior written notice. Termination of this Agreement shall not affect Licensee’s obligation to pay Royalties
with respect to Net Sales of Licensed Products made prior to such termination and shall not result in any refund to Licensee of any consideration previously paid to Medtronic. The parties acknowledge that, with respect to any other breaches by
Licensee or by any sublicensee, Affiliate or third party permitted under Section 2.2 of the terms, conditions or agreements of this Agreement, Medtronic may pursue its full legal and equitable rights and remedies against Licensee, including,
but not limited to, seeking monetary damages and/or an injunction. 
 (b) Either party may, by written notice to the other party (which
notice shall be effective upon receipt), terminate this Agreement in the event that such other party becomes insolvent, makes an assignment for the benefit of creditors, goes into liquidation or receivership or otherwise loses legal control of its
business. 
 (c) The parties acknowledge and agree that all rights and licenses granted pursuant to this Agreement are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(52) of the Bankruptcy Code, and that each party, as a licensee hereunder, shall
retain and may fully exercise all of its rights and elections under the Bankruptcy Code. 
 2.5. Delivery and Return of Confidential
Information. Upon termination of this Agreement or the licenses granted hereunder as provided herein, each party shall within 30 days of such termination return to the other party all of the other party’s Confidential Information.
Notwithstanding the foregoing each party shall have the right to retain one copy of such other party’s Confidential Information in its legal department files for archival purposes only. 
 2.6. Know-How Transfer; Access to Medtronic’s Employees and Consultant. 
 (a) Any expenses associated with the disclosure of know-how included within the Subject Technology to Licensee from SeaMed, Inc. relating to the Wet
Electrode Generator shall be the sole responsibility of Licensee. 
 (b) Promptly after the Effective Date, Medtronic shall provide to
Licensee copies of all tangible Subject Technology not previously disclosed to Licensee, including without limitation, those materials described on Exhibit B. 
 (c) Upon reasonable notice by Licensee to Medtronic, during the first three (3) months after execution of the Agreement, Medtronic will use reasonable efforts to obtain the services of [*], and make available the
following Medtronic employees: [*] and [*], available to meet with Licensee, subject to such individuals’ other commitments and schedules, for up to twenty hours each in the case of [*] (in the presence of one or more Medtronic representatives)
and [*] and up to ten hours for Mr. [*], to disclose to Licensee on Medtronic’s behalf those trade secrets and know-how included within the Subject Technology to allow Licensee to better understand and practice the inventions disclosed
therein to which the licenses under this Agreement pertain. Licensee shall pay [*] such amount as [*] and Licensee may mutually agree for the foregoing efforts of [*] and reimburse such individuals for any 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 5 

 reasonable travel and lodging expenses, if any, incurred by them for the purposes of such disclosure. Licensee shall also
reimburse Medtronic for any animal lab expenses relating to such disclosure incurred after the date of execution of this Agreement. No such disclosures by, nor payment to, such individuals shall be deemed to amend, negate, or otherwise modify the
exclusive consulting or employment relationship between such individuals, as the case may be, and Medtronic or to transfer or otherwise grant any rights to Licensee other than those rights to the Subject Technology specifically set forth in this
Agreement. The parties agree that, if desired by Licensee and [*], Licensee may enter into a formal consulting relationship with [*] permitting [*] to provide paid consulting services to Licensee, in addition to any such services provided to
Medtronic, concerning the Licensed Products in the Field of Use, subject to Medtronic’s approval, which approval shall not be unreasonably withheld. Licensee and Medtronic agree that any improvements, enhancements or modifications to the
Subject Technology developed, conceived or made by [*]: (i) while [*] is subject to a consulting relationship with Licensee; or (ii) to which Medtronic has ownership rights pursuant to its consulting agreement with [*], shall be deemed to
be owned by, and title thereto shall be transferred to, Medtronic and shall be deemed to be part of the Subject Technology, and as such shall be subject to Licensee’s rights hereunder. 
 (d) Medtronic shall provide written waivers from any non-compete and confidentiality obligations of [*] and such Medtronic employees to the extent
necessary to permit the disclosures and consulting contemplated under Section 2.6(c). In addition, Medtronic acknowledges (a) Licensee intends to hire M. Jacqueline Eastwood, a former Medtronic employee as its president, and Medtronic has
waived any non-compete and confidentiality obligations of Ms. Eastwood to the extent necessary to permit such employment, and (b) Licensee may have discussions with [*], a former Medtronic employee, concerning the Subject Technology and
Medtronic hereby waives any confidentiality obligations of [*] to the extent necessary to permit such discussions. 
 2.7. Right of
Notification. If Medtronic, at any time during the one (1) year period commencing on the date of execution of this Agreement, decides to license to [*] any other [*] technologies (including without limitation, any [*] technology for [*]),
it shall so notify the CEO or President of Licensee in writing or orally, prior to entering into any license agreement. As used in this Section 2.7, the term “[*] technology” shall mean any technology for the manufacture, use or sale
of any product or device that [*]. 
 ARTICLE 3 
 Royalties and Reports 
 3.1. License Fee. On the date of execution of this Agreement by the
parties, Licensee shall immediately pay to Medtronic a payment of [*] Dollars ($[*]) by wire transfer of such amount in immediately available funds to an account designated by Medtronic. Upon the successful completion by Licensee of [*] after the
Effective Date, Licensee shall immediately pay to Medtronic a payment of [*] Dollars ($[*]) by wire transfer of such amount in immediately available funds to an account designated by Medtronic. On the date of execution of this Agreement, Medtronic
will also receive 993,756 shares of the common stock, $.01 par value, of Licensee (“Common Stock”) and a Warrant, dated as of the Effective Date, to purchase up to 124,222 additional shares of Common Stock. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 6 

 Medtronic shall have the right to maintain its proportionate ownership of Licensee by investing in future financing
rounds along with other investors at that time pursuant to the terms of the Investors’ Rights Agreement by and among Licensee, Medtronic and certain investors, dated as of the Effective Date (the “Investors’ Rights Agreement”).

 3.2. Royalties on Net Sales by Licensee. Subject to the terms of this Agreement, Licensee shall pay to Medtronic a royalty (the
“Royalty” or “Royalties”) equal to a percentage of Net Sales of Licensed Products, as follows: 
 (a) The first [*]
Dollars ($[*]) of cumulative Net Sales of Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 after the Effective Date shall bear a royalty of seven and half percent (7.5%). 
 (b) The next [*] Dollars ($[*]) of cumulative Net Sales of Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted
under Section 2.2 shall bear a royalty of [*] percent ([*]%). 
 (c) The next [*] Dollars ($[*]) of cumulative Net Sales of Licensed
Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 shall bear a royalty of [*] percent ([*]%). 
 (d) Net Sales of Licensed Products by Licensee in excess of a cumulative [*] Dollars ($[*]) of Net Sales of Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 after the Effective
Date shall bear a royalty of two percent (2%). 
 3.3. Minimum Royalties. Licensee agrees to pay to Medtronic a minimum annual royalty
as set forth below. Licensee’s obligation to pay minimum annual royalties shall commence on January 1, 2003. Annual minimum royalties for each calendar year commencing on January 1, 2003 shall be (i) $[*] for 2003 and 2004, and
(ii) $300,000 for 2005 and each year thereafter. If Royalties on Net Sales of Licensed Products during the applicable calendar year are less than the applicable minimum annual royalty, the Licensee shall pay Medtronic the difference between
such Royalty and the minimum annual royalty. Such annual amounts shall be payable within forty-five (45) days after the end of the applicable calendar year. 
 3.4. Reports and Payments. Within forty-five (45) days after the end of each Quarter, Licensee shall provide Medtronic with a written report indicating (i) the amount of Net Sales of Licensed Products
by Licensee and by any sublicensee, Affiliate or third party permitted under Section 2.2 during such Quarter, and (ii) the amount of the Royalties due for such Quarter. Simultaneously with making such report, Licensee shall pay to
Medtronic the amount of royalties then due. 
 3.5. Records. Licensee agrees to keep and cause sublicensees, Affiliates and third
parties permitted under Section 2.2 to keep accurate written records sufficient in detail to enable Medtronic to verify the information contained in the reports described in Section 3.3. Such records for a particular Quarter shall be
retained by Licensee and such sublicensees, Affiliates and third parties for a period of not less than four years after the end of such Quarter. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 7 

 3.6. Audit of Records. Upon reasonable notice and during regular business hours Licensee and any
sublicensee, Affiliate and third party permitted under Section 2.2 shall from time to time (but no more frequently than once annually) make available the records referred to in Section 3.4 for audit by an independent nationally recognized
accounting firm selected by Medtronic to verify the accuracy of the reports provided to Medtronic. Such representatives shall execute a suitable confidentiality agreement reasonably acceptable to Licensee or such sublicensee, Affiliate or third
party prior to conducting such audit. Such representatives may disclose to Medtronic only their conclusions regarding the accuracy and completeness of the reports described in Section 3.3 and the records related thereto, and shall not disclose
confidential business information of Licensee or such sublicensee, Affiliate or third party to Medtronic without the prior written consent of Licensee or such sublicensee, Affiliate or third party. Such audits shall be at Medtronic’s cost and
expense; provided that if any such audit reveals underpayment of Royalties by five percent (5%) or more for any Quarter, then Licensee shall reimburse Medtronic for the fees and expenses of Medtronic’s independent auditors incurred by
Medtronic in connection with such audit. 
 ARTICLE 4 
 Additional Obligations 
 4.1. Restrictions on Use. Licensee will use all reasonable efforts to
ensure that all Licensed Products designed, developed, manufactured or sold by Licensee or its Affiliates, sublicensees or third parties with the use of any Subject Technology are not used outside of the Field of Use. 
 4.2. Confidentiality. The parties acknowledge that the patent applications listed in Exhibit A hereto, the inventions claimed therein, and all
trade secrets and know-how included within the Subject Technology constitute “Confidential Information” of Medtronic, subject to the exceptions set forth in Section 1.3. Each party agrees not to disclose or use any of the other
party’s Confidential Information except as expressly permitted in connection with the exercise of its rights hereunder. Each party shall not disclose the other party’s Confidential Information to any employee or consultant unless such
employee or consultant is obligated under a confidentiality agreement to maintain such other party’s Confidential Information in strict confidence, and not to use such information other than, in accordance with the terms of this Agreement. Each
party agrees to hold the other party’s Confidential Information in strict confidence and treat it with not less than the same degree of care to avoid disclosure as such party employs with respect to its own information of like importance.

 4.3. Infringement by Third Party. Licensee shall promptly notify Medtronic and Medtronic shall promptly notify Licensee in writing
if Medtronic or Licensee knows or has reason to believe that the rights of Medtronic or Licensee relating to the Subject Technology are being infringed by a third party. 
 4.4. Covenant Regarding Claims. Licensee agrees, for itself and for its Affiliates, sublicensees, successors, assigns, and other parties claiming any title or license to any Subject Technology, not to sue or
otherwise assert any claim against Medtronic, or any of 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 8 

 its Affiliates, successors, assigns, customers, vendors, or others in contractual privity with any of the foregoing, by
reason of or with respect to the use of such Subject Technology disclosed to Licensee as of the Effective Date or thereafter; provided, however, the foregoing shall not prevent any action on the part of Licensee, its Affiliates, successors or
assigns brought to enforce Licensee’s rights and Medtronic’s obligations under this Agreement. 
 4.5. Opinion of Counsel.
Licensee will deliver to Medtronic contemporaneously with the execution of this Agreement an opinion of Dorsey & Whitney, LLP, counsel to Licensee, substantially in the form as that provided to certain investors under Section 4.8 of
the Series A Convertible Preferred Stock Purchase Agreement between Licensee and such investors and executed contemporaneously with this Agreement (the “Investor Agreement”). 
 ARTICLE 5 
 Intellectual Property 
 5.1. No Representation or Warranty. EXCEPT AS PROVIDED IN ARTICLE 6, MEDTRONIC MAKES NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE
SUBJECT TECHNOLOGY OR ANY LICENSED PRODUCTS, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, PATENTABILITY, PATENT VALIDITY, NON-INFRINGEMENT, OR WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF
TRADE. 
 5.2. Control of Subject Technology. 
 (a) Medtronic shall have the sole and exclusive right, in Medtronic’s absolute discretion and at its sole expense, to prosecute any alleged infringement, misappropriation or misuse of the Subject Technology:
(i) outside the Field of Use, and shall retain all proceeds from prosecution up to the amount of any expenses of prosecution and investigation as well as retain all proceeds from prosecution in excess of expenses of prosecution and
investigation, and (ii) in the Field of Use, and shall retain all proceeds from prosecution up to the amount of any expenses of prosecution and investigation and shall retain fifty percent (50%) of all proceeds from such prosecution in
excess of expenses of prosecution and investigation and shall pay the balance to the Licensee. If Medtronic decides at any time not to commence or continue to prosecute any alleged infringement, misappropriation or misuse of the Subject Technology
in the Field of Use, it shall so notify Licensee in writing, and Licensee shall have the right, in its absolute discretion, to commence or continue such prosecution. If Licensee chooses to commence or continue such prosecution, Licensee shall
either: (i) fully fund such prosecution at its sole expense and shall retain all proceeds from prosecution up to the amount of any expenses of prosecution and investigation as well as retain seventy five percent (75%) of all proceeds from
prosecution in excess of expenses of prosecution and investigation and shall pay the balance to Medtronic, or (ii) fully fund such prosecution provided, however, that Licensee may supplement such funding by offsetting any prosecution expenses
against current Royalties due Medtronic under Section 3.2 and shall pay fifty (50%) of all proceeds from such prosecution to Medtronic without deducting from such proceeds any expenses of prosecution and investigation. If Licensee chooses
to commence or continue such prosecution, Licensee shall simultaneously 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 9 

 determine whether it wishes to choose option (i) or (ii) above and shall promptly notify Medtronic of its
choice, which shall be binding upon Licensee. If Licensee chooses option (ii) above, it shall offset prosecution expenses against Royalties on a calendar year basis. To the extent that Royalties in a calendar year exceed prosecution expenses in
the same calendar year, Licensee shall offset such expenses and pay the balance of the Royalties to Medtronic. In no event shall expenses offset by Licensee exceed the actual Royalties due Medtronic. At the request of the party prosecuting a suit,
the other party shall cooperate with the party prosecuting the suit in any such legal action either party may prosecute or defend under this Section 5.2(a). 
 (b) Medtronic shall have the sole right to [*] of any [*] included within the [*], any [*], or any other [*] related to [*] included within the [*]. The parties agree to consult in good faith regarding the foreign
countries in which [*]. Medtronic shall furnish Licensee with copies of any [*] concerning the [*] sufficiently in advance of [*] so as to give Licensee reasonable opportunity to review and comment. Medtronic shall also furnish to Licensee copies of
all substantive communications to and from [*] regarding [*] concerning the [*] within a reasonable time prior to filing such communication or promptly following receipt thereof, as the case may be, so as to give Licensee reasonable opportunity to
review and comment. Medtronic shall supply Licensee with a copy of each [*], together with notice of its [*]. 
 5.3. Indemnification.

 (a) Licensee shall indemnify, defend and hold harmless Medtronic, its Affiliates and Medtronic’s and its Affiliates’ respective
officers, directors, shareholders, employees and agents (collectively, all such indemnitees are referred to in this Section 5.3(a) as “Medtronic Indemnitees”) against and in respect of any and all claims, demands, losses, obligations,
liabilities, damages (and including without limitation compensatory and punitive damages), deficiencies, Actions, settlements, judgments, costs and expenses which the Medtronic Indemnitees may incur or suffer or with which it may be faced (including
reasonable costs and legal fees incident thereto or in seeking indemnification therefor) arising out of or based upon (i) any Product Liability Claims resulting from development, manufacture, use, or sale of any Licensed Product by Licensee or
any sublicensee, Affiliate or third party permitted under Section 2.2, or (ii) any breach of this Agreement by Licensee or any sublicensee, Affiliate or third party permitted under Section 2.2. 
 (b) Medtronic shall indemnify and hold harmless Licensee and its Affiliates and their respective officers, directors, shareholders, employees and agents
(collectively, all such indemnitees are referred to in this Section 5.3(b) as “Licensee Indemnitees”) against and in respect of any and all demands, losses, obligations, liabilities, damages (and including without limitation
compensatory and punitive damages), deficiencies, Actions, settlements, judgments, costs and expenses which the Licensee Indemnitees may incur or suffer or with which it may be faced (including reasonable costs and legal fees incident thereto or in
seeking indemnification therefor) arising out of or based upon any breach of this Agreement by Medtronic. 
 5.4. Limitation on
Liability. In no event shall Medtronic’s liability under this Agreement exceed [*] Dollars ($[*]) regardless of the form or basis of the action or claim, except with respect to (i) the grant by Medtronic of any license under the
Subject Technology to make, have made, use or sell Wet Electrode Products in the Field of Use that are Licensed Products, in the Territory, to any third 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 10 

 party; (ii) the manufacture, use or sale by Medtronic of Wet Electrode Products in the Field of Use that are
Licensed Products, in the Territory; (iii) breach by Medtronic of its obligations of non-disclosure and non-use under Section 4.2, or (iv) breach by Medtronic of its representations and warranties under Article 6. 
 5.5. Licensee Regulatory Interaction Rights. Notwithstanding Section 5.2 above, interaction with the regulatory agencies in any country,
including, without limitation the FDA, concerning Wet Electrode Products of Licensee in the Field of Use shall be exclusively conducted by Licensee and Licensee shall be the official company sponsor. Subject to Section 5.3(a) hereof, Licensee
shall have complete authority to act as Licensee, in its sole discretion, deems appropriate with respect to any such regulatory matter. 
 5.6. Licensee Marketing Rights. Nothing herein shall prevent or limit Licensee from setting its own prices for Licensed Products or determining Licensee’s marketing policies and practices in its sole discretion. 
 5.7. Trademark. Nothing in this Agreement shall be deemed to grant to Licensee any right to use the trademark “Medtronic”, the Medtronic
corporate logo, or any other trademark owned by Medtronic or its Affiliates. 
 ARTICLE 6 
 Representations & Warranties 
 6.1. Organization. Each party represents and warrants to the other party that such party is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its incorporation. 
 6.2. Authorization of Transaction. Each party represents and warrants to the other party that it has full power and authority (including full
corporate power and authority) to execute and deliver this Agreement and to perform its obligations hereunder. All necessary corporate proceedings (including any necessary approval by the board of directors) have been taken by such party to duly
authorize the execution, delivery, and performance of this Agreement by such party. This Agreement constitutes the valid and legally binding obligation of such party, enforceable against such party in accordance with its terms and conditions.

 6.3. No Conflicts. Medtronic represents and warrants to Licensee that it has not entered into any inconsistent prior obligations
concerning the Subject Technology that would prevent Licensee from exercising the rights being licensed to it hereunder. 
 6.4. No
Claims. Medtronic represents and warrants to it has not received written notification from a third party that the manufacture, use, importation or sale of the License Products under the license granted herein under the Subject Technology will
infringe any patents, copyrights, trade secrets or any other intellectual property rights of any third parties. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 11 

 ARTICLE 7 
 Miscellaneous 
 7.1. Assignment. Either party may assign or otherwise transfer its rights and
obligations under this Agreement to any successor in interest (by merger, share exchange, combination or consolidation of any type, operation of Law, purchase or otherwise), provided that such assignee or successor agrees to be bound by the terms
hereof, and provided further that in the event of such an assignment by Licensee, Licensee’s consulting agreement with [*], if any, pursuant to Section 2.6 and Licensee’s right of notice pursuant to Section 2.7 shall terminate
effective upon such transfer and assignment. Except as set forth above, Licensee may not assign or otherwise transfer its rights and obligations under this Agreement and any attempt to so assign or otherwise transfer its rights and obligations under
this Agreement shall represent a breach of the Agreement. 
 7.2. Entire Agreement. This Agreement, together with the Exhibits hereto,
the Investor Agreement and the Investors’ Rights Agreement, constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all previous proposals or agreements, oral or written, and all negotiations,
conversations or discussions heretofore had between the parties related to the subject matter of this Agreement. 
 7.3. Survival.
Articles 4 and 7 and Section 5.3 shall survive termination or expiration of this Agreement for any reason and continue thereafter in full force and effect. 
 7.4. Waiver, Discharge, etc. This Agreement may not be released, discharged, abandoned, changed or modified in any manner, except by an instrument in writing signed on behalf of each of the parties to this
Agreement by their duly authorized representatives. The failure of either party to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any such provision, nor in any way to affect the validity
of this Agreement or any part of it or the right of either party after any such failure to enforce each and every such provision. No waiver of any breach of this Agreement shall be held to be a waiver of any other or subsequent breach. 

7.5. Execution in Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same
agreement, and shall become a binding agreement when one or more counterparts have been signed by each party and delivered to the other party. 
 7.6. Titles and Headings: Construction. The titles and headings to Sections herein are inserted for the convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.
This Agreement shall be construed without regard to any presumption or other rule requiring construction hereof against the party causing this Agreement to be drafted. 
 7.7. Benefit. Nothing in this Agreement, expressed or implied, is intended to confer on any person other than the parties to this Agreement or their respective permitted successors or assigns, any rights,
remedies, obligations or liabilities under or by reason of this Agreement. 
 7.8. Notices. All notices or other communications to a
party required or permitted hereunder shall be in writing and shall be delivered personally or by telecopy (receipt confirmed) to such party (or, in the case of an entity, to an executive officer of such party) 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 12 

 or shall be given by certified mail, postage prepaid with return receipt requested, addressed as follows: 
 if to Licensee, to: 
 Virtuel Medical Devices, Inc.

 800 LaSalle Avenue, Suite 2250 
 Minneapolis, Minnesota 55402 
 Attention:       President 

	 	  	Facsimile number: (612) 607-2801 

 and if to Medtronic, to:

 Medtronic, Inc. 
 Corporate
Center 
 7000 Central Avenue N.E. 
 Minneapolis, Minnesota 55432 
 with separate copies thereof addressed to: 
  

			
	Attention:	    	General Counsel
		    	Facsimile number: (612) 572-5459
		
	Attention:	    	Vice President and Chief Development Officer
		    	Facsimile number: (612) 572-5404

 Licensee or Medtronic may change their respective above-specified recipient and/or mailing address by notice to
the other party given in the manner herein prescribed. All notices shall be deemed given on the day when actually delivered as provided above (if delivered personally or by telecopy) or on the day shown on the return receipt (if delivered by mail).

 7.9. Severability. If any provision of this Agreement is held invalid by a court of competent jurisdiction, the remaining
provisions shall nonetheless be enforceable according to their terms. Further, if any provision is held to be overbroad as written, such provision shall be deemed amended to narrow its application to the extent necessary to make the provision
enforceable according to applicable Law and shall be enforced as amended. 
 7.10. [*]. If requested by Medtronic, Licensee shall cause all
Licensed Products manufactured or sold under this license in the United States by it [*]. 
 7.11. Governing Law. This Agreement shall
be construed in accordance with Minnesota law, excluding its choice of law provisions. 
 [Signature Page Follows] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 13 

 IN WITNESS WHEREOF, each of the parties has caused this License Agreement to be executed in the manner
appropriate to each, effective as of the date first above written. 
  

			
	VIRTUEL MEDICAL DEVICES, INC.
		
	By:	 	 /s/ Jay Schmelter Aug 9, 1999

	Its:	 	President
	
	MEDTRONIC, INC.
		
	By:	 	 /s/ Michael D. Ellwein

	Its:	 	Vice President

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 Exhibit A 
 Subject Technology 
  

									
	Issued U.S. Patents
					
	 Medtronic Docket No
	 	 Title
	 	 Serial No.
	 	 Filing Date
	 	 Patent No.

	[*]	 	[*]	 	[*]	 	[*]	 	[*]
	
	Pending U.S. Utility Patent Applications
					
	 Medtronic Docket No.
	 	 Title
	 	 Serial No.
	 	 Filing Date
	 	 
	[*]	 	[*]	 	[*]	 	[*]	 	
	[*]	 	[*]	 	[*]	 	[*]	 	
	[*]	 	[*]	 	[*]	 	[*]	 	
	[*]	 	[*]	 	[*]	 	[*]	 	

  

	*	[*] 

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

							
	Pending U.S. Provisional Patent Applications
				
	 Medtronic Docket No.
	 	 Title
	 	 Serial No.
	 	 Filing Date

	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]	 	[*]

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 Exhibit B 
 Know-How Transfer 
 Pursuant to Section 2.6, Medtronic shall provide Licensee with the
following, subject to the withholding of material which is subject to an attorney-client privilege, whether in written or electronic format, relating specifically to Wet Electrode Products and Wet Electrode Generators: 
 [*] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 AMENDMENT NO. 1 TO LICENSE AGREEMENT 
 This Amendment No. 1 is an amendment to the License Agreement (the “License Agreement”) by and between TissueLink Medical, Inc., formerly
named Virtuel Medical Devices, Inc. (“Licensee”), and Medtronic, Inc. (“Medtronic”) dated as of August 9, 1999. This Amendment No. 1 is dated as of June 18, 2002. All capitalized terms not defined in this Amendment
No. 1 shall have the meanings set forth in the License Agreement. 
 The parties hereby agree that the License Agreement is amended as
follows: 
 ARTICLE 8 Name of Licensee. All references to Virtuel Medical Devices, Inc. shall be deemed to refer to the Licensee,
TissueLink Medical, Inc. 
 ARTICLE 9 Field of Use. Section 1.5 of the License Agreement is hereby amended as follows:

  

	 	(a)	The phrase “the [*] and [*] and the [*] and [*] and [*] and [*] and [*] thereof” in clause (ii) of the first sentence shall be replaced with the phrase “the [*]
and the [*] and [*] and [*] and [*] and [*] thereof (other than those of the [*] portion of the [*]).” 

  

	 	(b)	The following sentence shall be added after the second sentence: ‘[*] Applications’ shall mean any medical applications in [*] (including, but not limited to, [*])
relating to the [*] and [*].” 

 ARTICLE 10 Wet Electrode Products. Section 1.14 shall be amended to read in
its entirety as follows: 
 ‘Wet Electrode Products’ shall mean medical products, devices, or systems that employ an
electrode to deliver radio frequency energy and an electrically conductive fluid between the electrode and living tissue to apply radio frequency energy in medical applications in the Field of Use. Wet Electrode Products specifically exclude any
interstitial needle or intraluminal wire devices or products.” 
 ARTICLE 11 License Grant. Section 2.1 shall be amended to
read in its entirety as follows: 
 “Subject to the terms and conditions hereof, Medtronic hereby grants to Licensee (a) a
royalty-bearing and exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet Electrode Products in the Field of Use (other than [*]
Applications) that are Licensed Products throughout the Territory, (b) a royalty-bearing and co-exclusive license, subject to the rights retained by Medtronic and described in the last sentence of this Section 2.1, under the Subject
Technology, with no 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 18 

 right to grant sublicenses, to make, have made, use and sell Wet Electrode Products for [*] Applications
in the Field of Use that are Licensed Products throughout the Territory, and (c) a royalty-bearing and non-exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2 hereof, to
make, have made, use and sell Wet Electrode Generators in the Field of Use that are Licensed Products throughout the Territory. Medtronic has no right to grant licenses or sublicenses to the Subject Technology to make, have made, use or sell Wet
Electrode Products for [*] Applications in the Field of Use that are Licensed Products in the Territory; provided, however, that Medtronic may grant one or more Permitted [*] Product Licenses (as defined in Section 3.2) on or
after June 18, 2003; provided, further, however, that, subject to any confidentiality limitations applicable to Medtronic in connection with such grant, Medtronic shall give Licensee notice of the granting of any Permitted [*]
Product License within fifteen (15) days of the effective date of such grant, (such notice to identify the licensee or sublicensee and the litigation or dispute relating to such grant and to describe the scope of the license in reasonable
detail), and shall provide Licensee with additional information upon reasonable request in order to enable Licensee to verify that such license or sublicense was granted in accordance with the terms of this Agreement.” 
 ARTICLE 12 Sublicensing and Distribution. Section 2.2 shall be amended by adding the following phrase before the first word of the first
sentence: “Except as otherwise provided in Section 2.1, ....” 
 ARTICLE 13 Royalty on [*] Licensed Products.
Section 3.2 shall be amended as follows: 
  

	 	13.1.	All references to “Net Sales of Licensed Products” shall be replaced with the phrase, “Net Sales of Licensed Products excluding [*] Licensed Products.”

  

	 	13.2.	The following paragraph shall be added after the last sentence of Section 3.2: 

 “For purposes of this Agreement, ‘[*] Licensed Products’ shall mean Licensed Products marketed for [*] Applications. For purposes of this Agreement, ‘Permitted [*] Product
License’ shall mean a license or sublicense to make, have made, use and sell Wet Electrode Products for [*] Applications in the Field of Use that are Licensed Products in the Territory granted by Medtronic to a third party that is not an
Affiliate of Medtronic as is necessary or appropriate (as determined by Medtronic in its sole discretion) solely for the 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 19 

 purpose of settling litigation between Medtronic and the third party relating to Medtronic’s
intellectual property rights or settling another bona fide dispute between Medtronic and the third party relating to Medtronic’s intellectual property rights. Subject to the terms of this Agreement, Licensee shall pay to Medtronic a royalty
equal to a percentage of Net Sales of [*] Licensed Products as follows: 
 (e) The first [*] Dollars ($[*]) of cumulative Net
Sales of [*] Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 after the Effective Date shall bear a royalty of seven and half percent (7.5%). 
 (f) The next [*] Dollars ($[*]) of cumulative Net Sales of [*] Licensed Products by Licensee and by any sublicensee, Affiliate and third
party permitted under Section 2.2 shall bear a royalty of [*] percent ([*]%). 
 (g) The next [*] Dollars ($[*]) of
cumulative Net Sales of [*] Licensed Products by Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 shall bear a royalty of [*] percent ([*]%). 
 (h) Net Sales of [*] Licensed Products by Licensee in excess of a cumulative [*] Dollars ($[*]) of Net Sales of [*] Licensed Products by
Licensee and by any sublicensee, Affiliate and third party permitted under Section 2.2 after the Effective Date shall bear a royalty of two percent (2%). 
 (i) Notwithstanding the foregoing, in the event Medtronic grants a Permitted [*] Product License, then (A) the provisions of clauses
(e) - (h) of this Section 3.2 shall no longer apply and (B) Net Sales of [*] Licensed Products on and after the effective date of such Permitted [*] Product License by Licensee and by any sublicensee, Affiliate and third party
permitted under Section 2.2 shall bear a royalty of [*] percent ([*]%).” 
 ARTICLE 14 Minimum Royalties. Section 3.3
shall be amended by replacing the phrase “Royalties on Net Sales of Licensed Products” in the fourth sentence with the phrase “Royalties on Net Sales of Licensed Products excluding [*] Licensed Products.” 
 ARTICLE 15 Intellectual Property. The following subparagraph shall be added to Section 5.2 and designated as subsection (c): 
 “(c) In the event that Medtronic (i) [*] included within the Subject Technology which relates to the Field of Use, Licensee shall have the
right to exercise complete control, at Licensee’s expense and upon written notice to 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 20 

 Medtronic, over such [*]. Medtronic shall copy Licensee on all correspondence with respect to
Medtronic’s [*] included within the Subject Technology such that Licensee has the reasonable opportunity to take such action as may be necessary to [*] in the event Medtronic [*]. For purposes of this Section 5.2(c), [*] shall include a
reference to [*].” 
 ARTICLE 16 Notices. The following address replaces the address listed for Licensee in Section 7.8 of
the License Agreement: 
 TissueLink Medical, Inc. 
 One Washington Center 
 Suite 400 
 Dover, NH 03820 
 Attn: Chief Executive Officer 
 Facsimile number: (603) 742-1488 
 ARTICLE 17 Miscellaneous. Except as otherwise expressly
amended by this Amendment, the terms and conditions of the License Agreement shall remain in full force and effect. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
 [Signature pages follow.] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 21 

 IN WITNESS WHEREOF, the parties to this Amendment have executed this Amendment No. 1 to the License
Agreement as of the date first written above. 
  

			
	MEDTRONIC, INC.
		
	By:	 	 /s/ Michael D. Ellwein

	Its:	 	VP & CDO
	
	TISSUELINK MEDICAL, INC.
		
	By:	 	 /s/ M. Jacqueline Eastwood

	Its:	 	Pres. & CEO

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 22 

 AMENDMENT NO. 2 
 TO 
 LICENSE AGREEMENT 
 THIS AMENDMENT NO. 2 TO LICENSE AGREEMENT (the “Amendment”) is entered into as of March 1, 2004 (the “Effective Date”), by and
between TissueLink Medical, Inc. (“Licensee”) and Medtronic, Inc. and it amends that certain License Agreement dated as of August 9, 1999 between the parties as amended by Amendment No. 1 to License Agreement dated June 18,
2002 (the “License Agreement”). 
 The parties hereby agree that the License Agreement is amended as follows: 
 1. Minimum Royalties. The last sentence of Section 3.3 of the License Agreement is deleted and replaced with the following: 
 “Within forty-five (45) days after the end of calendar years 2004, 2005 and 2006, Licensee shall: (i) execute and deliver to Medtronic a
promissory note on the terms and in the form of the promissory note set forth in Exhibit A (the “Form Note”) in the principal amount of the annual amount due Medtronic pursuant to this Section 3.3 with respect to such calendar year;
and (ii) execute and deliver to Medtronic a warrant on the terms and in the form set forth in Exhibit B (the “Form Warrant”) entitling Medtronic to purchase that number of shares equal to: (A) such annual amount due Medtronic
pursuant to this Section 3.3 with respect to such calendar year multiplied by .[*]; divided by (B) the Exercise Price (as defined in the Form Warrant). Any annual amount due Medtronic pursuant to this Section 3.3
applicable to periods from and after January 1, 2007, shall be payable within forty-five (45) days after the end of the applicable calendar year.” 
 2. Royalty Payments. The last sentence of Section 3.4 of the License Agreement is deleted and replaced with the following: 
 “Simultaneously with delivery to Medtronic of a report for any Quarter from January 1, 2004 through December 31, 2006, Licensee shall: (i) execute and deliver to Medtronic a promissory note in
favor of Medtronic on the terms and in the form of the Form Note in the principal amount of the quarterly Royalty due Medtronic for such Quarter; and (ii) execute and deliver to Medtronic a warrant on the terms and in the form of the Form
Warrant for that number of shares equal to (A) the amount of the Royalty due Medtronic for such Quarter multiplied by .[*]; divided by (B) the Exercise Price (as defined in the Form Warrant). For Quarters from and after
January 1, 2007, simultaneously with making any report pursuant to this Section 3.4, Licensee shall pay to Medtronic the amount of royalties then due.” 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 23 

 3. No Conflicts. A new Section 3.7 shall be added to the License Agreement and shall read in
its entirety as follows: 
 “Licensee represents and warrants to Medtronic that the execution, delivery and performance by Licensee of
the promissory notes and warrants contemplated by Sections 3.3 and 3.4 will not: (a) result in a breach or violation of, or default under, any material contract to which Licensee is a party or by which it is bound (including without limitation
the Credit Agreement with Brown Brothers Harriman & Co. dated as of September 3, 2002, as amended, and related credit documents and the Convertible Promissory Note issued to Century Medical Inc. dated April 29, 2002, and the
related Distribution Agreement with Century Medical Inc.); (b) result in the creation or imposition of a lien or other encumbrance upon, or the forfeiture of, any material asset or assets of Licensee; or (c) result in a breach or violation
of, or default under, the certificate of incorporation or by-laws of Licensee.” 
 3. Miscellaneous. Except as otherwise
expressly amended by the Amendment No. 2, the terms of the License Agreement shall remain in full force and effect. This Amendment may be executed in any number of counterparts, each of which shall be deemed as original, but all of which
together shall constitute one and the instrument. 
 [Signature page follows.] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 24 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment No. 2 to License Agreement to be
executed in the manner appropriate for each, and to be dated as of the date first above-written. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	 /s/ Joseph Army / /s/ M. Jacqueline Eastwood

	Name:	 	Joseph Army / M. Jacqueline Eastwood
	Title:	 	VP & CFO / Pres. & CEO
	
	MEDTRONIC, INC.
		
	By:	 	 /s/ Michael D. Ellwein

	Name:	 	Michael D. Ellwein
	Title:	 	VP & CDO

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 Execution Copy 
  
 EXHIBIT A 
 FORM PROMISSORY NOTE 
  

					
	$                    	 		 	Minneapolis Minnesota

                         , 2004 
 FOR VALUE RECEIVED, the undersigned, TissueLink Medical, Inc., a Delaware corporation (“Maker”), hereby promises to pay to the order of Medtronic, Inc., (“Payee”), at Payee’s principal place
of business, or such other place as Payee under this Promissory Note may from time to time designate in writing, in lawful money of the United States of America the principal sum of
                         and     /100 Dollars
($                    ) [Amount to equal amount that would otherwise be paid as royalty pursuant to License Agreement for
applicable time period through December 31, 2006]. 
 The principal of this Note and accrued interest shall be due and payable
in full on March 31, 2007. Maker shall pay interest on the outstanding principal amount of this Note from the date hereof until payment in full hereof at an annual rate equal to ten percent (10%). Notwithstanding the foregoing, from and after
the occurrence of any Event of Default (as defined below) and during the continuance thereof, the interest rate shall be equal to eighteen percent (18%) per annum. 
 Until payment in full of the principal amount set forth above, interest on the outstanding principal amount hereof shall be payable quarterly, commencing [first day of next calendar quarter] and shall be
payable the first day of each quarter thereafter. Interest as aforesaid shall be charged for the actual number of days elapsed over a year consisting of three hundred sixty-five (365) days on the actual daily outstanding balance hereof.

 Maker may prepay this Note in whole or in part at any time without premium or penalty. Any partial prepayment of this Note shall be
applied first to any unpaid interest on this Note. 
 Upon the occurrence of an Event of Default and the acceleration of this Note as
provided below, this Note shall be immediately due and payable. The occurrence of any one or more of the following events shall constitute an “Event of Default”: 
 (a) Maker shall fail to make when due, whether by acceleration or otherwise, any payment of principal of, or interest on, this Note; or

 (b) Maker shall materially breach any agreement, covenant, condition, provision or term contained in the License Agreement
or the documents relating thereto; or 
 (c) If (i) Maker shall (1) be or become insolvent, or (2) apply for or
consent to the appointment of, or the taking of possession by, a receiver, custodian, trustee, liquidator or the like of the person or of all or a substantial part of the person’s property, or (3) commence a voluntary case under any
bankruptcy, insolvency, reorganization, arrangement, readjustment of debt, dissolution, liquidation or similar proceeding under the laws of any jurisdiction, or (4) file a petition seeking to take 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 26 

 Execution Copy 
  
 advantage of any other law relating to bankruptcy, insolvency, reorganization, winding up or composition or adjustment of
debts, or (5) admit in writing its inability to pay its debts as they mature, or (6) make an assignment for the benefit of its creditors; or (ii) a proceeding or case shall be commenced, without the application or consent of Maker,
and which is not dismissed within 30 days after such commencement, in any court of competent jurisdiction, seeking (1) the liquidation, reorganization, dissolution, winding up or the composition or adjustment of debts of Maker, (2) the
appointment of a trustee, receiver, custodian or liquidator or the like of the person or of all or any substantial part of Maker’s property, or (3) similar relief in respect of Maker under any law relating to bankruptcy, insolvency,
reorganization, winding up or composition or adjustment of debts); or 
 (d) The maturity of any indebtedness (other than
indebtedness under this Note and whether owed to the Payee or to others) of Maker shall be accelerated, or Maker shall fail to pay any such indebtedness when due or, in the case of such indebtedness payable on demand, when demanded, or any event
shall occur or condition shall exist and shall continue for more than the period of grace, if any, applicable thereto and shall have the effect of causing or permitting (any required notice having been given and grace period having expired) the
holder of any such indebtedness in such aggregate amount or any trustee or other person acting on behalf of such holder to cause, such indebtedness to become due prior to its stated maturity or to realize upon any collateral given as security
therefor; or 
 (e) Maker shall fail to pay, withhold, collect or remit any material tax or tax deficiency when assessed or
due or notice of any state or federal tax lien shall be filed or issued. 
 If (a) any Event of Default described in paragraph
(c) above shall occur, the outstanding unpaid principal balance of this Note and the accrued interest thereon shall automatically become immediately due and payable; or (b) any other Event of Default shall occur and be continuing and such
Event of Default is not cured by Maker within ten (10) days after written notice from Payee, then Payee may declare that the outstanding unpaid principal balance of this Note and the accrued and unpaid interest thereon to be immediately due and
payable, whereupon this Note, all accrued and unpaid interest thereon and all such other obligations shall immediately become due and payable, in each case without further demand or notice of any kind, all of which are hereby expressly waived,
anything in this Note to the contrary notwithstanding. In addition, upon any Event of Default and so long as such Event of Default continues, Payee may exercise all rights and remedies under any other instrument, document or agreement between Maker
and Payee and enforce all rights and remedies under any applicable law. 
 The indebtedness evidenced by this Note is hereby expressly
subordinated and subject and junior in right of payment, to the extent and in the manner hereinafter set forth below in this paragraph, to the prior payment in full of all Senior Indebtedness (as defined below in this paragraph): 
 As used in this Note, the term “Senior Indebtedness” shall mean the principal of and interest on all indebtedness, obligations and liabilities
of Maker under the Credit Agreement dated as of September 3, 2002, as amended on March 3, 2004, by and between Maker and Brown Brothers Harriman & Co. (the “BBH Credit Agreement”), the Security Agreement (as defined in
the BBH Credit Agreement) and the Notes (as defined in the BBH Credit Agreement). 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 27 

 Execution Copy 
  
 Subject to the provisions of subparagraph (d) below, no payment or distribution of any character, whether in cash, securities or other
property, shall be made on account of or applied to the principal of this Note prior to the earlier of: (i) the payment in full of the Senior Indebtedness or (ii) the stated maturity dates of the principal of and interest on the Senior
Indebtedness (the dates described in clauses (i) and (ii) are each referred to as the “Senior Indebtedness Maturity Date”). The foregoing limitation shall not be deemed to prohibit Maker from issuing warrants (or shares of
capital stock issuable upon exercise of such warrants) to Payee pursuant to the Amendment (as defined below). 
 If there should occur any
receivership, insolvency, assignment for the benefit of creditors, bankruptcy, reorganization or arrangements with creditors (whether or not pursuant to bankruptcy or other insolvency laws), sale of all or substantially all of the assets,
dissolution, liquidation or any other marshalling of the assets and liabilities of Maker, then prior to the Senior Indebtedness Maturity Date (i) no amount shall be paid by Maker in respect of the principal of this Note at the time outstanding,
unless and until the principal of and interest on the Senior Indebtedness then outstanding shall be paid in full, and (ii) no claim or proof of claim shall be filed with Maker by or on behalf of Payee that shall assert any right to receive any
payments in respect of the principal of this Note, except subject to the payment in full of the principal of and interest on all of the Senior Indebtedness then outstanding. 
 In the event that an Event of Default occurs and this Note is accelerated prior to the Senior Indebtedness Maturity Date, no payment shall be made in
respect of the principal of this Note unless, within thirty (30) days after the date Maker is required to give notice to the holder of Senior Indebtedness of the Event of Default (to the extent required by the terms of the Senior Indebtedness
instrument(s)), the maturity of such Senior Indebtedness shall not have been accelerated. If the maturity of such Senior Indebtedness is accelerated within such 30-day period, no payment shall be made in respect of the principal of this Note prior
to the payment in full of the Senior Indebtedness. 
 In the event any direct or indirect payment or distribution shall be received by the
holder of this Note in contravention of the provisions of subparagraph (b), (c) or (d) above, then such payment or distribution shall be held in trust for and shall be paid over or delivered to the holder of Senior Indebtedness, until all
Senior Indebtedness shall have been paid in full, after giving effect to any concurrent payment or distribution, or provision therefor, to the holder of Senior Indebtedness. 
 Nothing otherwise contained in this paragraph is intended to or shall impair, as among Maker, its creditors other than the holder of Senior Indebtedness,
and Payee, the obligations of Maker, which are, subject to the terms of this paragraph, absolute and unconditional, to pay the Note, as and when the same shall become due and payable in accordance with its terms, or to affect the relative rights of
Payee and creditors of Maker other than the holder of Senior Indebtedness, nor shall anything herein or therein prevent Payee from exercising all rights permitted it hereunder upon the acceleration of this Note, subject to the rights, if any, under
this paragraph of the holder of Senior Indebtedness in respect of cash, property or securities of Maker received upon the exercise of any such remedy. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 28 

 Execution Copy 
  
 By its acceptance of this Note, Payee agrees to execute and deliver such documents as may be reasonably requested from time to time by Maker
or the holder of Senior Indebtedness in order to implement the foregoing provisions of this paragraph. 
 This Note is issued in connection
with, and subject to the terms and conditions of, that certain Amendment No. 2 to License Agreement dated March 1, 2004 (the “Amendment”), among Maker and Payee. Any transferee of this Note accepts it subject to the terms and
conditions of the Amendment. 
 This Note shall be interpreted and the rights and liabilities of the parties hereto determined in accordance
with the laws of the State of Minnesota. If any provision of this Note or the application thereof shall be held to be void or unenforceable by any court of competent jurisdiction, such defect shall not affect the remainder of this Note, which shall
continue in full force and effect. Maker agrees to reimburse the Payee upon demand for all reasonable expenses paid or incurred by Payee (including costs and fees and expenses of legal counsel) in connection with the collection and enforcement of
this Note. 
 Whenever in this Note reference is made to Payee or Maker, such reference shall be deemed to include, as applicable, a
reference to their respective successors and assigns. The provisions of this Note shall be binding upon Maker and its successors and assigns, and shall inure to the benefit of Payee and its successors and assigns. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	  

	Its:	 	  

  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 29 

 Execution Copy 
  
 AMENDMENT NO. 3 
 TO 
 LICENSE AGREEMENT 
 THIS AMENDMENT NO. 3 TO LICENSE AGREEMENT (the “Amendment”) is entered into as of July 18, 2006 (the “Effective Date”), by and between TissueLink Medical, Inc. (“Licensee”) and
Medtronic, Inc. and it amends that certain License Agreement dated as of August 9, 1999 between the parties as amended by Amendment No. 1 to License Agreement dated June 18, 2002 and Amendment No. 2 to License Agreement dated
March 1, 2004 (the “License Agreement”). 
 The parties hereby agree that the License Agreement is amended as follows:

 1. Field of Use. Section 1.5 of the License Agreement is hereby amended as follows: 
 (a) Clause (ii) of the first sentence shall be deleted and the clauses following clause (ii) shall be renumbered, so that the first sentence
reads in its entirety as follows: 
 “ ‘Field of Use’ shall mean any [*] applications in [*] (including, but not limited
to, [*] during and following [*]) other than and hereby expressly excluding applications relating to: (i) the [*] and [*]; (ii) the [*], the [*] and the structures of the [*]; (iii) the [*]; and (iv) the [*] when access by [*]
means.” 
 (b) The following sentence shall be added after the last sentence: 
 “ ‘[*] Applications’ shall mean any [*] applications in [*] (including, but not limited to, [*] during and following [*]) relating
to the [*] and the [*] and [*] and [*] and [*] and [*] thereof (other than those of the [*] portion of the [*]).” 
 2. License
Grant. Section 2.1 shall be amended to read in its entirety as follows: 
 “Subject to the terms and conditions hereof,
Medtronic hereby grants to Licensee (a) a royalty-bearing and exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet Electrode
Products in the Field of Use (other than [*] Applications and [*] Applications) that are Licensed Products throughout the Territory, (b) royalty-bearing and co-exclusive license, subject to the rights retained by Medtronic and described in the
last sentence of this Section 2.1, under the Subject Technology, with no right to grant sublicenses to make, have 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 30 

 Execution Copy 
  
 made, use and sell Wet Electrode Products for [*] Applications and [*] Applications in the Field of Use that are Licensed
Products throughout the Territory, and (c) a royalty-bearing and non-exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet
Electrode Generators in the Field of Use that are Licensed Products throughout the Territory. Medtronic has no right to grant licenses or sublicenses to the Subject Technology to make, have made, use or sell Wet Electrode Products for [*]
Applications or [*] Applications in the Field of Use that are Licensed Products in the Territory, provided, however, that Medtronic may grant one or more Permitted [*] Product Licenses (as defined in Section 3.2) on or after
June 18, 2003 and that Medtronic may grant one or more Permitted [*] Product Licenses (as defined in Section 3.2) on or after July 18, 2007; provided, further, however, that subject to any confidentiality limitations applicable
to Medtronic in connection with such grant, Medtronic shall give Licensee notice of the granting of any Permitted [*] Product License or any Permitted [*] Product License within fifteen (15) days of the effective date of such grant, (such
notice to identify the license or sublicense and the litigation or dispute relating to such grant and to describe the scope of the license in reasonable detail), and shall provide Licensee with additional information upon reasonable request in order
to enable Licensee to verify that such license or sublicense was granted in accordance with the terms of this Agreement.” 
 3.
Royalty on [*] Licensed Products. Section 3.2 shall be amended as follows: 
 (a) All references to “Net Sales of Licensed
Products excluding [*] Licensed Products” shall be replaced with the phrase “Net Sales of Licensed Products excluding [*] Licensed Products and [*] Licensed Products.” 
 (b) The following sentences shall be added after the last sentence of Section 3.2: 
 “For purposes of this Agreement, [*] Licensed Products’ shall mean Licensed Products marketed for [*] Applications. ‘Permitted
[*] Product License’ shall mean a license or sublicense to make, have made, use and sell Wet Electrode Products for [*] Applications in the Field of Use that are Licensed Products in the Territory granted by Medtronic to a third party that
is not an Affiliate of Medtronic as is necessary or appropriate (as determined by Medtronic in its sole discretion) solely for the purpose of settling litigation between Medtronic and the third party relating to Medtronic’s intellectual
property rights or settling another bona fide dispute between Medtronic and the third party relating to Medtronic’s intellectual property rights. Subject to the terms of this Agreement, Licensee shall pay to Medtronic a royalty equal to the
applicable percentage of Net Sales of [*] Licensed Products set forth in paragraphs (e) – (h) of this Section 3.2 (calculated as if the reference to Net Sales of [*] Licensed Products in such paragraphs instead referred to Net
Sales of [*] Licensed Products).” 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 31 

 Execution Copy 
  
 4. Minimum Royalties. Section 3.3 shall be amended as follows: 
 (a) The phrase “Royalties on Net Sales of Licensed Products excluding [*] Licensed Products” in the fourth sentence shall be replaced with the
phrase “Royalties on Net Sales of Licensed Products excluding [*] Licensed Products and [*] Licensed Products.” 
 (b) The phrase
“calendar years 2004, 2005 and 2006” in the fifth sentence shall be replaced with the phrase “calendar years 2004, 2005, 2006, 2007 and 2008.” 
 (c) The phrase “January 1, 2007” in the last sentence shall be replaced with the phrase “January 1, 2009.” 
 5. Royalty Payments. Section 3.4 shall be amended as follows: 
 (a) The phrase “January 1,
2004 through December 31, 2006” in the third sentence shall be replaced with the phrase “January 1, 2004 through December 31, 2008.” 
 (b) The phrase “multiplied by .[*]” in the second to last sentence shall be replaced with the phrase “multiplied by .[*].” 
 (c) The phrase “January 1, 2007” in the last sentence shall be replaced with the phrase “January 1, 2009.” 
 6. Exhibit A. Exhibit A to the License Agreement (Form Promissory Note) shall be amended as follows: 
 (a) The phrase “March 31, 2007” in the second paragraph shall be replaced with the phrase “March 31, 2009.” 
 (b) The phrase “ten percent (10%)” in the second paragraph shall be replaced with the phrase “eleven and three-quarters percent
(11.75%).” 
 (c) The phrase “that certain Amendment No. 2 to License Agreement dated March 1, 2004 (the
‘Amendment’)” in the first full paragraph on page 4 shall be replaced with the phrase “that certain Amendment No. 2 to License Agreement dated March 1, 2004 and Amendment No. 3 to License Agreement dated
July 18, 2006 (collectively, the ‘Amendment’).” 
 7. Warrant Issuance. As additional consideration for this
Amendment No. 3, Licensee shall execute and deliver to Medtronic a warrant on the terms and in the form of the Form Warrant for that number of shares equal to (A) the aggregate amount of promissory notes issued by Licensee to Medtronic
outstanding as of the date hereof multiplied by .[*]; divided by (B) [*]. 
 8. Miscellaneous. Except as otherwise
expressly amended by this Amendment No. 3, the terms of the License Agreement shall remain in full force and effect. This Amendment may be executed in any number of counterparts, each of which shall be deemed as original, but all of which
together shall constitute one and the instrument. 
 [Signature page follows.] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 32 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment No. 3 to License Agreement to be
executed in the manner appropriate for each, and to be dated as of the date first above-written. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	 /s/ M. Jacqueline Eastwood

	Name:	 	M. Jacqueline Eastwood
	Title:	 	Pres. & CEO
	
	MEDTRONIC, INC.
		
	By:	 	 /s/ Michael D. Ellwein

	Name:	 	Michael D. Ellwein
	Title:	 	VP & CDO

  

  
  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 AMENDMENT NO. 4 
 TO 
 LICENSE AGREEMENT 
 THIS AMENDMENT NO. 4 TO LICENSE AGREEMENT (the “Amendment”) is entered into as of April 1, 2007 (the “Effective Date”), by and
between TissueLink Medical, Inc. (“Licensee”) and Medtronic, Inc., and it amends that certain License Agreement dated as of August 9, 1999 between the parties as amended by Amendment No. 1 to License Agreement dated June 18,
2002, Amendment No. 2 to License Agreement dated March 1, 2004 and Amendment No. 3 to License Agreement dated July 18, 2006 (the “License Agreement”). 
 The parties hereby agree that the License Agreement is amended as follows: 
 1. Field of Use. Section 1.5 of the License Agreement is hereby amended so that the first sentence reads in its entirety as follows: 
 “ ‘Field of Use’ shall mean any [*] applications in [*] (including, but not limited to, [*]) other than and hereby expressly
excluding applications relating to: (i) the [*] and [*]; (ii) the [*], the [*] and the [*] of the [*]; (iii) the [*]; and (iv) the accessing of any of the [*] described in clauses (i) – (iii) above by means of the
[*]. 
 2. Licensed Products. Section 1.7 of the License Agreement is hereby amended so that it reads in its entirety as follows:

 “Licensed Products” shall mean Wet Electrode Products, Interstitial Needle Products and Wet Electrode Generators, the
manufacture, use or sale of which uses or incorporates any of the Subject Technology.” 
 2. Subject Technology. 
 (a) Section 1.11(iii) of the License Agreement is hereby amended so that it reads in its entirety as follows: 
 “(iii) all invention disclosures, trade secrets and know-how owned by Medtronic prior to the date of this Agreement that relate specifically to the
Wet Electrode Products, Interstitial Needle Products (as defined in Section 3.2) or Wet Electrode Generators disclosed in the patents and patent applications listed in Exhibit A and” 
 (b) Exhibit A of the License Agreement shall be amended to add those patents listed on Schedule 1 of this Amendment. 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 34 

 3. Wet Electrode Generator(s). Section 1.13 of the License Agreement is hereby amended so
that it reads in its entirety as follows: 
 “Wet Electrode Generator(s)” shall mean the medical generators
primarily intended to provide power directly to Wet Electrode Products or Interstitial Needle Products in the Field of Use.” 
 4.
License Grant. Section 2.1 shall be amended to read in its entirety as follows: 
 “Subject to the terms and conditions
hereof, Medtronic hereby grants to Licensee (a) a royalty-bearing and exclusive license under the Subject Technology, with the right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet
Electrode Products in the Field of Use (other than [*] Applications and [*] Applications) that are Licensed Products throughout the Territory, (b) a royalty-bearing and co-exclusive license, subject to the rights retained by Medtronic and
described in the last sentence of this Section 2.1, under the Subject Technology, with no right to grant sublicenses, to make, have made, use and sell Wet Electrode Products for [*] Applications and [*] Applications in the Field of Use that are
Licensed Products throughout the Territory, (c) a royalty-bearing and co-exclusive license, subject to the rights retained by Medtronic and described in the last sentence of this Section 2.1, under the Subject Technology, with no right to
grant sublicenses, to make, have made, use and sell Interstitial Needle Products in the Field of Use that are Licensed Products throughout the Territory and (d) a royalty-bearing and non-exclusive license under the Subject Technology, with the
right to grant sublicenses subject to the terms of Section 2.2 hereof, to make, have made, use and sell Wet Electrode Generators in the Field of Use that are Licensed Products throughout the Territory. Medtronic has no right to grant licenses
or sublicenses to the Subject Technology to make, have made, use or sell (i) Wet Electrode Products for [*] Applications or [*] Applications in the Field of Use that are Licensed Products in the Territory or (ii) Interstitial Needle
Products in the Field of Use that are Licensed Products in the Territory, provided, however, that Medtronic may grant one or more Permitted [*] Product Licenses (as defined in Section 3.2) on or after June 18, 2003, one or more
Permitted [*] Product Licenses (as defined in Section 3.2) on or after July 18, 2007, and one or more Permitted Interstitial Needle Product Licenses (as defined in Section 3.2) on or after April 1, 2008; provided, further,
however, that subject to any confidentiality limitations applicable to Medtronic in connection with such grant, Medtronic shall give Licensee notice of the granting of any Permitted [*] Product License, Permitted [*] Product License or Permitted
Interstitial Needle Product License within fifteen (15) days of the effective date of such grant, (such notice to identify the licensee or sublicensee and the litigation or dispute relating to such grant and to describe the scope of the license
in reasonable detail), and shall provide Licensee with additional information upon reasonable request in order to enable Licensee to verify that such license or sublicense was granted in accordance with the terms of this Agreement.” 

5. Royalty on Interstitial Needle Products. Section 3.2 shall be amended so that the following sentences shall be added after the last
sentence of Section 3.2: 
 “For purposes of this Agreement, ‘Interstitial Needle Products’ shall mean any
interstitial needle or intraluminal wire devices or products. ‘Permitted Interstitial Needle Product License’ shall mean a license or sublicense to make, have made, 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 35 

 use and sell Interstitial Needle Products in the Field of Use that are Licensed Products in the Territory
granted by Medtronic to a third party that is not an Affiliate of Medtronic as is necessary or appropriate (as determined by Medtronic in its sole discretion) solely for the purpose of settling litigation between Medtronic and the third party
relating to Medtronic’s intellectual property rights or settling another bona fide dispute between Medtronic and the third party relating to Medtronic’s intellectual property rights. Subject to the terms of this Agreement, Licensee shall
pay to Medtronic a royalty equal to [*] percent ([*]%) of Net Sales of Interstitial Needle Products that are Licensed Products by Licensee and by any sublicensee, Affiliate or third party permitted under Section 2.2.” 
 6. Minimum Royalties. Section 3.3 shall be amended so that the phrase “Royalties on Net Sales of Licensed Products excluding [*]
Licensed Products and [*] Licensed Products” in the fourth sentence shall be replaced with the phrase “Royalties on Net Sales of Licensed Products excluding [*] Licensed Products, [*] Licensed Products and Interstitial Needle
Products.” 
 7. Correction to Titles of Exhibits. The last sentence of Section 3.3 of the License Agreement, Section 1
of Amendment No. 2 to License Agreement and Section 6 of Amendment No. 3 to License Agreement shall be amended so that all references to “Exhibit A” are changed to read “Exhibit C,” and all references to
“Exhibit B” are changed to read “Exhibit D.” 
 8. Medtronic Right to Designate Director. In partial consideration
of Medtronic, Inc.’s execution of this Amendment No. 4, Licensee represents and warrants to Medtronic, Inc. that Licensee has caused its Amended and Restated Certificate of Incorporation to be amended, to the extent necessary, to provide
Medtronic, Inc. with a right to designate one (1) member of the Board of Directors of Licensee. Such right shall continue in effect until the earliest to occur of (i) the consummation of a Qualified Initial Public Offering (as defined in
such Amended and Restated Certificate of Incorporation), (ii) a Deemed Liquidation Event (as defined in such Amended and Restated Certificate of Incorporation) or (iii) the expiration or termination of the License Agreement. 
 9. Miscellaneous. Except as otherwise expressly amended by this Amendment the terms of the License Agreement shall remain in full force and
effect. This Amendment may be executed in any number of counterparts, each of which shall be deemed as original, but all of which together shall constitute one and the instrument. 
 [Signature page follows.] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 36 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment No. 4 to License Agreement to be
executed in the manner appropriate for each, and to be dated as of the date first above-written. 
  

			
	TISSUELINK MEDICAL, INC.
		
	By:	 	 /s/ Joseph Army

	Name:	 	Joseph Army
	Title:	 	Chief Operations Officer
	
	MEDTRONIC, INC.
		
	By:	 	 /s/ Gary L. Ellis

	Name:	 	Gary L. Ellis
	Title:	 	Chief Financial Officer

  
  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 Schedule 1 
 Interstitial Needle Patents 
 To Be Added to Exhibit A 
  

							
	 Title
	 	 Serial No.
	 	 Filing Date
	 	 Patent No.

	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]
	 [*]
	 	[*]	 	[*]	 	[*]

 [*] 
  

  

			
	[*] =	 	Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]